SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                    FORM 10-K

|X|  Annual report pursuant to Section 13 or 15(d) of the Securities Exchange
           Act of 1934 for the fiscal year ended December 31, 1998 or

|_| Transition report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.

                            NU SKIN ENTERPRISES, INC.
         --------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                     001-12421               87-0565309
----------------------------      ---------------------      ------------------
(State or other jurisdiction      (Commission File No.)         (IRS Employer
    of incorporation)                                        Identification No.)

                              75 West Center Street
                                Provo, Utah 84601
         --------------------------------------------------------------
          (Address of principal executive offices, including zip code)

       Registrant's telephone number, including area code: (801) 345-6100

           Securities registered pursuant to Section 12(b) of the Act:

        Title of each class                 Name of exchange on which registered
Class A Common Stock, $.001 par value              New York Stock Exchange

        Securities registered pursuant to Section 12(g) of the Act: None

        Indicate by check mark whether the  Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days. Yes|X| No |_|

        Based on the closing  sales price of the Class A Common Stock on the New
York Stock Exchange on March 26, 1999, the aggregate  market value of the voting
stock  (Class  A and  Class  B  Common  Stock)  held  by  non-affiliates  of the
Registrant was $704,691,842. For purposes of this calculation, voting stock held
by officers, directors, and affiliates has been excluded.

        As of March 25,  1999,  33,165,315  shares of the  Registrant's  Class A
Common  Stock,  $.001  par  value  per  share,  and  54,606,905  shares  of  the
Registrant's Class B Common Stock, $.001 par value per share, were outstanding.

Documents  incorporated  by  reference.  Portions of the  Company's  1998 Annual
Report to  Stockholders  to be  furnished  to the  stockholders  of the  Company
pursuant to Rule 14a-3(b) in connection with Registrant's 1999 Annual Meeting of
Stockholders are attached hereto as Exhibit 13, and are  incorporated  herein by
reference  into  Parts  II and  IV of  this  Form.  Portions  of  the  Company's
definitive  Proxy  Statement  for  the  Registrant's   1999  Annual  Meeting  of
Stockholders to be filed with the Securities and Exchange  commission within 120
days after the  Registrant's  fiscal year end are  incorporated  by reference in
Part III of this report.

Indicate by check mark if disclosure of delinquent  filers  pursuant to Item 405
of Regulation  S-K is not contained  herein,  and will not be contained,  to the
best  of  the  Registrant's   knowledge,  in  definitive  proxy  or  information
statements  incorporated  by  reference  in Part  III of this  Form  10-K or any
amendment to this Form 10-K. |_|

                                TABLE OF CONTENTS

PART I  .......................................................................1

ITEM 1.  Business..............................................................1
         General...............................................................1
         Recent Developments...................................................2
         Business Divisions ...................................................4
         Product Summary.......................................................6
         Distribution System..................................................12
         Product Development..................................................17
         Sourcing and Production..............................................19
         Regional Profiles....................................................20
         Competition..........................................................22
         Intellectual Property................................................23
         Government Regulation................................................23
         Employees............................................................27
         Risk Factors.........................................................27
ITEM 2.  Properties...........................................................35
ITEM 3.  Legal Proceedings....................................................35
ITEM 4.  Submission of Matters to a Vote of  Security Holders.................36

PART II ......................................................................37

ITEM 5.  Market for Registrant's Common Equity and Related Stockholder
             Matters..........................................................37
ITEM 6.  Selected Financial Data..............................................37
ITEM 7.  Management's Discussion and Analysis of Financial Condition and
             Results of Operations............................................37
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk ..........37
ITEM 8.  Financial Statements and Supplementary Data..........................37
ITEM 9.  Changes In and Disagreements With Accountants on Accounting and
             Financial Disclosure.............................................37

PART III......................................................................38

PART IV ......................................................................38

ITEM 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K.....38

Signatures....................................................................44

                                        i

                           FORWARD LOOKING STATEMENTS

         THIS ANNUAL REPORT ON FORM 10-K, IN  PARTICULAR  "ITEM 7.  MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL  CONDITION AND RESULTS OF  OPERATIONS"  AND
"ITEM 1. BUSINESS," INCLUDE  "FORWARD-LOOKING  STATEMENTS" WITHIN THE MEANING OF
SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THESE STATEMENTS
REPRESENT THE COMPANY'S EXPECTATIONS OR BELIEFS CONCERNING,  AMONG OTHER THINGS,
FUTURE REVENUE, EARNINGS, AND OTHER FINANCIAL RESULTS, PROPOSED ACQUISITIONS AND
NEW PRODUCTS,  ENTRY INTO NEW MARKETS,  FUTURE OPERATIONS AND OPERATING RESULTS,
FUTURE  BUSINESS  AND MARKET  OPPORTUNITIES.  THE COMPANY  WISHES TO CAUTION AND
ADVISE READERS THAT THESE STATEMENTS  INVOLVE RISK AND UNCERTAINTIES  THAT COULD
CAUSE ACTUAL  RESULTS TO DIFFER  MATERIALLY  FROM THE  EXPECTATIONS  AND BELIEFS
CONTAINED  HEREIN.  FOR A SUMMARY OF  CERTAIN  RISKS  RELATED  TO THE  COMPANY'S
BUSINESS, SEE "ITEM 1. BUSINESS -- RISK FACTORS" BEGINNING ON PAGE 27.

         THE COMPANY HAS ENTERED  INTO A LETTER OF INTENT TO ACQUIRE BIG PLANET,
INC. AND THE REMAINING PRIVATE AFFILIATES OPERATING IN NORTH AMERICA (OUTSIDE OF
THE UNITED STATES). THIS FORM 10-K CONTAINS INFORMATION  CONCERNING THE BUSINESS
OF BIG PLANET,  INC. AND THE PRIVATE  AFFILIATES AND THE  ANTICIPATED  EFFECT OF
SUCH PROPOSED ACQUISITIONS ON THE BUSINESS OF THE COMPANY. THE COMPANY IS IN THE
PROCESS OF  FINALIZING  DEFINITIVE  AGREEMENTS  WITH  RESPECT  TO SUCH  PROPOSED
ACQUISITIONS.  THE  PROPOSED  ACQUISITIONS  ARE  SUBJECT TO  SEVERAL  CONDITIONS
INCLUDING   COMPLETION  OF  DEFINITIVE   DOCUMENTATION,   RECEIPT  OF  NECESSARY
REGULATORY AND THIRD-PARTY APPROVALS,  COMPLETION OF THE COMPANY'S DUE DILIGENCE
REVIEW,  AND  APPROVAL  BY  THE  STOCKHOLDERS  OF BIG  PLANET  AND  THE  PRIVATE
AFFILIATES.  THERE CAN BE NO ASSURANCE  THAT THE PROPOSED  ACQUISITIONS  WILL BE
COMPLETED AS PLANNED.

         Unless the context requires otherwise, references to the Company are to
Nu Skin Enterprises,  Inc. and its  subsidiaries.  In this Annual Report on Form
10-K,  references to "dollars" and "$" are to United  States  dollars.  Nu Skin,
Pharmanex,  Interior  Design  Nutritionals,  "6S Quality  Process",  and IDN are
trademarks of the Company.  Big Planet and InterNetworking are trademarks of Big
Planet,  Inc. The  italicized  product  names used in this Annual Report on Form
10-K are product names and also, in certain cases, trademarks of the Company.

                                     PART I

ITEM 1.  BUSINESS

General

         Nu Skin Enterprises,  Inc. (the "Company") is a leading,  global direct
selling  company  that  currently  distributes  premium  quality  personal  care
products and nutritional supplements. Upon completion of the planned acquisition
of Big  Planet,  Inc.  discussed  below,  the Company  will also offer  Internet
connectivity, e-commerce,  telecommunications, and other technology products and
services to consumers in the United States. The Company currently operates in 27
countries  throughout  North Asia,  Southeast Asia, North America,  Europe,  and
South America and is reported to be one of the largest direct selling  companies
in the world.

         The Company  distributes  its  products  exclusively  through a network
marketing  system.  The Company currently has a network of nearly 500,000 active
distributors located throughout its 27 markets that purchase products for resale
to consumers  and for personal  consumption.  Nu Skin was among the first direct
selling companies to compensate distributors in their home countries for product
sales  around  the  world.  Under  the  Company's  "Global  Compensation  Plan,"
distributors can develop a seamless network of downline distributors  throughout
the  world  and  across  divisions.  The  Company  believes  that its  extensive
distributor  force and the Global  Compensation  Plan provide the Company with a
competitive  advantage  in gaining  quick access to new  geographic  markets and
rapid market penetration of new products.

                                      -1-

         During the past twelve months the Company has taken significant actions
to broaden the Company's  business both  geographically and across product lines
and to gain greater control over its product and business opportunity offerings.
These actions include:

       *      The  acquisition  of  Pharmanex,  Inc.  ("Pharmanex"),  a  premier
              developer of nutritional supplements.

       *      The expansion of operations into five new markets--Brazil, Sweden,
              Denmark, Poland, and the Philippines.

       *      The acquisition of Nu Skin operations in the United States.

       *      The  execution  of a letter of intent to acquire Big Planet,  Inc.
              ("Big  Planet")  and  the  Company's   other  private   affiliates
              operating in Canada, Mexico, and Guatemala.

These  initiatives  were designed to leverage the Company's  primary asset,  its
sales and distribution channel and related expertise,  by strengthening existing
product  lines,  providing  the Company  with  greater  control over product and
business  opportunity  offerings,  expanding the Company's  geographic  markets,
establishing   a  technology   division,   fortifying   the  Company's   support
infrastructure, and positioning the Company for further growth.

         The   acquisition   of  the  United   States  market  and  the  planned
acquisitions  of Big Planet and the remaining  private  affiliates  operating in
North  America  should  also  simplify  the  Nu  Skin  corporate   structure  by
consolidating all of Nu Skin's  operations under the Company.  This should allow
the Company to  transition  from a geographic  management  focus to a strategic,
product-based  business  model  along  three  general  product  divisions.   The
divisions will offer the following three distinct business  opportunities,  each
specifically  designed for the network marketing  distribution channel, and each
managed and directed by dedicated, distinct management teams:

         Nu Skin Personal Care. The Company's original product line and business
         opportunity,  offering over 100 premium quality  personal care products
         in several  categories:  facial care,  body care,  hair care, and color
         cosmetics,  as well as specialty products such as sun protection,  oral
         hygiene, and fragrance.

         Pharmanex.  A  nutritional  supplement  division  offering a variety of
         nutritional  supplements  in  several  categories:   multi-vitamin  and
         mineral products and supplements that are currently  marketed under the
         IDN (Interior Design  Nutritional)  trademark  including  LIFEPAK,  the
         Company's flagship  nutritional  supplement,  five proprietary  natural
         supplements  and a broad  line of  standardized  botanical  supplements
         acquired  in  the  acquisition  of  Pharmanex,  and a  line  of  sports
         nutritional and general health solutions.

         Big Planet.  A  communications  and  technology  products  and services
         division that offers Internet access and related services,  e-commerce,
         telecommunications,  unified  communications,  and  on-line  and CD-ROM
         educational products.

Recent Developments

         Acquisition  of Nu Skin  International.  At the beginning of 1998,  the
Company operated as the exclusive  distribution vehicle for NSI in the countries
of Japan,  Taiwan, Hong Kong (including Macau),  Thailand,  and South Korea, and
had the right to expand only into  certain  other Asian  markets  including  the
Philippines,  the People's Republic of China, Vietnam, Singapore,  Malaysia, and
Indonesia.   In  February  1998,  the  Company   commenced   operations  in  the
Philippines.  In  March  1998,  the  Company  acquired  NSI  and  certain  other
affiliated  entities  for $70.0  million in  preferred  stock,  the  issuance of
long-term notes payable to the  stockholders  of the NSI totaling  approximately
$6.2 million,  and the assumption of liabilities of approximately $173.8 million
in  notes  that  were  distributed  by NSI  prior  to  the  closing  to the  NSI
stockholders as a distribution of all previously  earned and  undistributed  "S"
corporation  earnings.  The  preferred  stock was  subsequently  converted  into
2,978,159 shares of

                                      -2-

Class A Common Stock after  giving  effect to the  cancellation  of 8,504 shares
following  an  adjustment  in the  purchase  price based on the audited  closing
balance sheet of NSI. Through this acquisition, the Company obtained:

       *      Nu Skin's existing operations in New Zealand,  Australia,  and ten
              countries in Europe, and the right to all other future markets.

       *      Ownership  of  all  rights  to  the  Nu  Skin  distributor  force,
              including all distributor  agreements and the Global  Compensation
              Plan, and all trade names, trademarks,  product formulations,  and
              other  intellectual  property  rights and know how associated with
              the Nu Skin  business and products,  all of which were  previously
              made available to the Company through a license from NSI.

       *      Greater control over product development,  manufacturing, pricing,
              and the strategic development of the Nu Skin products and business
              offerings.

         Acquisition  of  Pharmanex.  In  October  1998,  the  Company  acquired
Pharmanex,  a research  and  development  company  and  manufacturer  of natural
nutritional  supplements,  in exchange  for the  issuance of  approximately  4.0
million  shares of the Class A Common Stock of the Company and the assumption of
approximately  $34.0  million in  liabilities.  The  Company  believes  that the
acquisition of Pharmanex provides it with:

       *      Significant  additional product research and development resources
              with a staff  of more  than 40  M.D.and/or  Ph.D.  scientists  and
              laboratory facilities in China and the United States.

       *      Important clinical research and collaboration agreements and other
              relationships with several major universities in the United States
              and the  People's  Republic  of China  ("China")  that the Company
              believes  will  enhance  its  ability  to  perform  cost-effective
              clinical trials to help substantiate product claims.

       *      A line of  existing  proprietary  nutritional  and a broad line of
              botanical   supplements   including   CHOLESTIN,   a   nutritional
              supplement shown to help maintain healthy cholesterol levels.

       *      Manufacturing  capabilities  with the acquisition of an extraction
              facility in China.

         Acquisition  of North American  Affiliates.  In March 1999, the Company
acquired certain assets of its privately-held  affiliate, Nu Skin USA, Inc., and
terminated the exclusive license and distribution agreements it had entered into
with such entity. Prior to this transaction, Nu Skin USA, Inc. had the exclusive
right to sell the Company's  products and services within the United States.  In
addition,  the Company has also  entered  into a letter of intent to acquire its
other  private  affiliates  operating in Canada,  Mexico,  and  Guatemala  (such
affiliates,  together with Nu Skin USA, Inc., are hereinafter referred to as the
"North  American  Affiliates").  The total  consideration  paid or to be paid in
connection with such transactions  includes cash payments of approximately $19.0
million and the assumption of certain liabilities (approximately $8.0 million in
the Nu Skin USA transaction).

         Acquisition of Big Planet. In addition,  the Company has entered into a
letter of intent to acquire Big Planet, Inc. The consideration will consist of a
cash  payment of  approximately  $14.5  million,  the  issuance of a  three-year
promissory note in the amount of approximately  $14.5 million and the assumption
of certain liabilities. In addition, prior to such acquisition,  Big Planet will
accelerate the employee  stock awards and options of most Big Planet  management
personnel and employees and cash them out. Unvested shares and options which are
not accelerated  will be converted into shares of, and options to acquire shares
of, the Class A Common  Stock of the  Company.  The  Company  also will  provide
management personnel of Big Planet and certain key employees with certain equity
and cash  incentives,  some of which  will be issued or paid only if Big  Planet
achieves certain agreed

                                      -3-

upon  performance  criteria.  The  acquisition  of Big  Planet is subject to the
satisfaction  of  various   conditions,   including   completion  of  definitive
documentation,  obtaining necessary  regulatory and third-party  approvals,  the
satisfactory completion of the Company's due diligence work, and approval by the
shareholders of Big Planet. The proposed acquisition is expected to be completed
by June 30, 1999. There can be no assurance,  however,  that all such conditions
will be satisfied or that unanticipated factors will not arise which could cause
the transaction to be delayed or not to be completed.  See "Risk Factors - Risks
Related to the Integration of Recent and Contemplated Acquisitions."

Business Divisions

Nu Skin Personal Care

         Nu Skin  Personal  Care is the  Company's  original  product  line  and
business opportunity and currently consists of premium quality lines of over 100
personal care products in the areas of facial care,  body care,  hair care, skin
whiteners,  and  color  cosmetics,  as well as  specialty  products  such as sun
protection,  oral hygiene,  and  fragrances.  According to the WWD Beauty Report
International,  at the end of 1997,  the Company was the tenth largest  cosmetic
company in Asia.

         Nu Skin Personal Care's strategy is to distribute high quality personal
care products and treatments that utilize advanced  formulas.  For example,  the
Company was one of the first companies to market topical applications of various
vitamins  including  Vitamins  E,  C and  A.  Other  examples  include  the  MHA
REVITALIZING  products,  which utilize alpha and beta hydroxy acids to fight the
signs of aging,  and CELLTREX,  a  concentrated  solution of aloe vera and other
ingredients,  designed  to improve  the skin's  moisture  content.  The  Company
recently entered into a nine-year contract with Stanford University for directed
research  on  skin  care  products  and  established  the  Nu  Skin  Center  for
Dermatological  Research at Stanford  University's  School of Medicine.  Nu Skin
Personal  Care also seeks to take  advantage of the  Company's  highly  educated
distributor  force to provide  consumers  with a high level of  information  and
instruction about the products and guidelines for using them effectively.

Pharmanex

         Following  the  acquisition  of  Pharmanex,   the  Company  merged  its
previously  existing Interior Design Nutritional  products division ("IDN") with
Pharmanex.   The  Company  believes  that  combining  Pharmanex's  research  and
development  engine and its proprietary  nutritional  and botanical  supplements
with IDN's  existing  product  development  resources  and  vitamin  and mineral
products,  including IDN's flagship product, LIFEPAK, helps position the Company
to further penetrate the growing  nutritional  supplement  market.  The combined
Pharmanex/IDN  division  offers over 60 nutritional  supplements  and nutri-food
products.

         The  Company  believes  that  the  nutritional   supplement  market  is
expanding  throughout  the  world  because  of  changing  dietary  patterns,  an
increasingly  health-conscious  population,  and a growing  amount of scientific
evidence supporting the benefits of using vitamin and natural self-care products
and  supplements.  The Company  believes that its  nutritional  supplements  are
particularly  well suited to network  marketing  because the average consumer is
often uneducated about nutritional supplements. The Company believes that direct
selling is a more  effective  method  than  traditional  retailing  channels  in
educating  consumers  regarding  the  benefits of  nutritional  supplements  and
differentiating  the quality and benefits of its products  from those offered by
competitors.  Because there are numerous providers of nutritional supplements of
varying degrees of quality,  the Company believes that individual  attention and
testimonials  by  distributors  provide  information  and comfort to a potential
consumer.   In  January  1999,  the  Company   discontinued   selling  Pharmanex
nutritional  supplements  in  traditional  retail  channels  where they had been
distributed  by Pharmanex  prior to its  acquisition  by the Company.  Pharmanex
products are now available  exclusively through the Company's distributor force,
which the Company  believes can more effectively  educate  consumers about these
products on a  person-to-person  basis.  Consistent  with this personal  selling
approach,  Pharmanex will allow independent pharmacies to be distributors of its

                                      -4-

products  because these  smaller  pharmacies  tend to provide more  personalized
service  and   accommodate   the  flow  of   information   to   consumers  on  a
person-to-person basis.

         Pharmanex utilizes available scientific  literature,  existing research
and clinical studies, and its own research work and clinical studies,  including
placebo  controlled,  double blind studies, in the evaluation and development of
its products and in connection with confirming the efficacy of its products. Two
of the Company's premier products,  LIFEPAK,  an advanced,  uniquely  formulated
multivitamin/mineral   supplement,  and  CHOLESTIN,  a  proprietary  nutritional
supplement that promotes healthy  cholesterol  levels,  have been the subject of
recent independent clinical studies that have demonstrated the efficacy of these
products.  The Company has also  supported the creation of two research  centers
for  nutritional  supplements:  the UCLA  Center  for Human  Nutrition/Pharmanex
Phytochemical  Laboratory and the Pharmanex Institute for Cardiovascular  Health
and Sports Nutrition.  The Company believes that the proprietary supplements and
the broad line of botanical  supplements  acquired in the Pharmanex  acquisition
complement the Company's  multivitamin and nutritional  products and provide the
Company with a strong  portfolio of products for both the herbal and  non-herbal
segments of the nutritional supplement market.

Big Planet

         The Internet is rapidly emerging as a global medium for communications,
sharing information, and electronic commerce. An industry analyst, International
Data  Corporation,  estimates  that the  number  of Web  users  will  grow  from
approximately 100 million in 1998 to over 200 million by 2001. The recent growth
of the Internet and  electronic  commerce is  effecting  significant  changes in
information  delivery  and product  purchasing.  In  addition,  deregulation  of
telecommunications  and the growth in wireless  communications  have resulted in
changes and  opportunities  in the  telecommunications  markets.  Big Planet was
founded  for the  purpose of  providing  a new  business  opportunity  involving
technology products and services that attempts to:

       *      Take advantage of the  opportunities  provided by the rapid growth
              of the technology and communication markets;

       *      Appeal to a new demographic of customers and distributors; and

       *      Utilize the strength and  competitive  advantages of the Company's
              distribution   system  to  reach  new  market   segments   of  the
              marketplace.

         The core strategy of Big Planet is to be an  "InterNetworking"  company
that  combines  the  global  Internet  revolution  with the power of  one-to-one
relationships  to improve the way people "learn,  communicate,  work,  shop, and
play.(TM)"  The Company  believes  that there is a high degree of  compatibility
between technology  products and the Company's  distribution  system. Big Planet
seeks to leverage  the direct  selling  expertise of the  Company's  distributor
force to assist the large  number of  consumers  who want to take  advantage  of
technology's  latest  offerings  but do not  know  how  or  are  intimidated  by
technology's constant innovations.  Big Planet's  representatives are trained to
provide the assistance and training  necessary to help customers  understand and
take advantage of the latest products. The Company believes that the combination
of its  distribution  system,  a highly  motivated  sales force,  and the proper
training  of its Big  Planet  distributors  will  provide  the  Company  with an
opportunity to help take technology to the masses.

         Big  Planet's  product  strategy  is to  offer an  integrated  suite of
products and services for education,  telecommunications,  Internet access,  and
electronic  commerce.  Big Planet believes that multiple connections to the home
enhances customer  retention by providing a broad range of integrated  services.
Big Planet's  communication  and  technology  products and services are designed
specifically  for  consumers  and  small  businesses  who  desire a  responsive,
single-source  provider of  Internet  connectivity,  communications  and on-line
purchasing via e-commerce. Big Planet currently generates revenue from providing
Internet  access,   telecommunications

                                      -5-

products and services  including long distance and paging,  from sales of a wide
selection  of products  through its  e-commerce  store and from sales of various
CD-ROM and on-line educational products.

Product Summary

         In 1998,  the  Company  offered  products in two  distinct  categories:
personal  care  products,  mainly  marketed  under the  trademark "Nu Skin," and
nutritional supplements,  mainly marketed under the trademark "IDN." The Company
is committed to building its brand name and distributor and customer  loyalty by
selling personal care products with advanced  formulas and nutritional  products
that are backed by science and appeal to broad  markets.  The Company's  product
philosophy  is to combine  the best of science and nature and include in each of
its products  high quality  ingredients  which provide  desired  benefits to the
consumer.

         The Company does not  distribute  all of its personal care products and
nutritional  products in each market.  When commencing  operations in a country,
the Company selects a group of initial products to be distributed in such market
and adds  additional  products as the market  matures and develops.  The Company
determines  which  products will be marketed in a specific  country based on the
likelihood  of the  particular  product's  success  in the  market  as  well  as
applicable  regulatory  approvals and requirements.  In certain of the Company's
markets,  the Company has  reformulated  products to satisfy certain  regulatory
requirements  with respect to product  ingredients  and/or  preservatives and to
meet the preferences of consumers in those markets.  See "Government  Regulation
Regulation of Personal Care Products and Nutritional  Supplements." In addition,
the Company will also  develop  products  designed for a particular  market when
appropriate.  Following the  completion of the  acquisition  of Big Planet,  the
Company will also offer  Internet and  telecommunication  products and services.
See "Recent Developments."

         Presented below are the dollar amount and percentage of revenue of each
of the two product  categories and other sales aid revenue for each of the years
ended December 31, 1996, 1997, and 1998. This table should be read in connection
with the information  presented under the caption  "Management's  Discussion and
Analysis of  Financial  Condition  and Results of  Operations"  contained in the
Company's Annual Report to Stockholders, which is incorporated by reference into
this Form 10-K and which  discusses the costs  associated  with  generating  the
aggregate revenue presented.



                           Revenue by Product Category
                          (Dollar Amounts in Thousands)

                                                Year Ended             Year Ended            Year Ended
                                            December 31, 1996      December 31, 1997      December 31, 1998
                                           -------------------    -------------------    -------------------
Product Category                               $          %          $           %          $           %
---------------------------------------    --------     ------    --------     ------    --------     ------
                                                                                     
Nu Skin Personal Care..................    $554,974      72.9%    $604,078      63.4%    $531,915      58.2%
Pharmanex/IDN (Nutritional Supplements)     160,288      21.0      297,300      31.2      334,257      36.6
Sales Aids                                   46,376       6.1       52,044       5.4       47,322       5.2
                                           --------     ------    --------     ------    --------     ------
        Total..........................    $761,638     100.0%    $953,422     100.0%    $913,494     100.0%
                                           ========     ======    ========     ======    ========     ======


                                      -6-

Nu Skin Personal Care Products

         The  Company's  current  personal  care  products  are divided into the
following  lines:  facial  care,  body care,  hair care,  color  cosmetics,  sun
protection,  oral hygiene,  fragrances,  and certain speciality products. The Nu
Skin Personal Care product line consists of over 100 products.  The Company also
offers  product sets that  includea  variety of products in each product line as
well as small,  sample-size packages to facilitate product sampling by potential
consumers. The product sets are especially popular during the opening phase of a
new country,  when  distributors and consumers are anxious to purchase a variety
of products, and during holiday and gift giving seasons in each market.

         The  following is a brief  description  of each line within the Nu Skin
Personal Care division offered by the Company as of December 31, 1998:

         Facial Care.  The facial care line is the premier line of the Company's
personal  care  products  and consists of 20  different  specialized  treatment,
cleanser,  and moisturizer products.  The specialized treatment products utilize
advanced  formulas and ingredients  designed for specific skin care  conditions.
These special  treatment  products  include:  MHA REVITALIZING  products,  which
utilize  alpha and beta  hydroxy  acids to help  fight the signs of aging;  SKIN
BRIGHTENING COMPLEX, designed to diminish the appearance of discoloration caused
by sun exposure;  FACE LIFT WITH ACTIVATOR,  a product designed to stimulate and
firm skin; and CLARIFEX PH MUD ACNE TREATMENT.

         The goal of the facial care line of cleansers  and  moisturizers  is to
allow users to cleanse thoroughly without causing dryness and to moisturize with
effective  humectants  that allow the skin to attract  and retain  vital  water.
These products include CELLTREX, a concentrated  solution of aloe vera and other
ingredients,  designed to improve the skin's moisture content,  and REJUVENATING
CREAM, one the Company's most popular personal care products.  Other facial care
products  include  CLEANSING  LOTION,  FACIAL  SCRUB,  EXFOLIANT  SCRUB,  FACIAL
CLEANSING BAR, CLAY PACK, PH BALANCE FACIAL TONER, NAPCA MOISTURIZER,  INTENSIVE
EYE COMPLEX,  HPX HYDRATING GEL,  CLARIFEX  CLEANSING  SCRUB,  CLARIFEX MUD, and
ALPHA EXTRA FACE.

         Body Care. The Company's  line of body care products  relies on premium
quality  ingredients to cleanse and condition skin. The cleansers are formulated
without soap, and the  moisturizers  contain light but effective  humectants and
emollients.  The body care line includes  DERMATIC  EFFECTS,  a body  contouring
lotion  containing  extracts of hibiscus and malvaceae that has been  clinically
demonstrated  to aid in preventing  the  appearance of cellulite and aging skin.
The  Company's  body  care  line  currently   consists  of  11  other  products:
ANTIBACTERIAL BODY CLEANSING GEL, LIQUID BODY LUFRA, BODY SMOOTHER, HAND LOTION,
NAPCA MOISTURE MIST,  BODY BAR, BODY CLEANSING GEL,  ENHANCER,  JUNGAMALS  CRAZY
CROCODILE CLEANER, ALPHA EXTRA BODY, and MHA REVITALIZING BODY LOTION.

         Hair Care.  The Company's hair care line,  HAIRFITNESS,  is designed to
meet the needs of people with all types of hair and hair  problems.  Focusing on
the  condition of the scalp and its impact on hair quality,  the Company's  hair
care products use  water-soluble  conditioners like panthenol to reduce build-up
on the scalp and to promote  healthy  hair.  HAIRFITNESS  includes  12  products
featuring  ceregen, a revolutionary  wheat hydrocolloid  complex of conditioning
molecules,  designed to enhance hair repair and moisture control aspects: 3 IN 1
SHAMPOO, MOISTURIZING SHAMPOO, BALANCING SHAMPOO, VITAL SHAMPOO, DEEP CLARIFYING
SHAMPOO,  GLACIAL  THERAPY,   WEIGHTLESS  CONDITIONER,   LUXURIOUS  CONDITIONER,
CONDITIONING  DETANGLER  SPRAY,  STYLING GEL, HOLDING SPRAY, and MOUSSE (Styling
Foam). The Company also carries DERMANATOR  SHAMPOO,  an anti-dandruff  shampoo,
and JUNGAMALS TIGER TANGLE TAMER SHAMPOO,  a shampoo for children.  In 1999, the
Company also plans to introduce a hair care line, KANURE,  specifically designed
and  formulated  for the Brazilian  market to address the natural  properties of
severely dry and curly hair.

         Color Cosmetics. The Company's color cosmetic line, NU COLOUR, consists
of 13  products  with  over 150 SKU's  including  MOISTURESHADE  LIQUID  FINISH,
MOISTURESHADE PRESSED POWDER, BLUSH, EYE SHADOW,  MASCARA,

                                      -7-

EYELINER,  LIP LINER,  LIPSTICK,  DRAMATTEICS  LIP  PENCILS,  LIP  GLOSS,  CREME
CONCEALER,  FINISHING POWDER,  and BROW PENCIL. Nu Skin Personal Care intends to
relaunch the NU COLOUR line in the second quarter of 1999 with new packaging and
new shades.

         Sunscreen.  The  Company's  line of  SUNRIGHT  products  is designed to
provide a variety of sun screen  protection with  non-irritating  and non-greasy
products.  The sun  protection  line  includes a sun  preparation  product  that
prepares the skin for the drying impact of the sun, five sun screen alternatives
with various levels of SPF, and a sun screen lip balm.

         Oral  Hygiene.  AP-24,  a line  of  oral  health  care  products  which
incorporates  anti-plaque technology designed to help prevent plaque build-up 24
hours  a  day,  is  exclusively  licensed  to the  Company,  together  with  the
associated trademark, for sale in the direct selling channel under the trademark
AP-24.   This  product  line  includes  AP-24  ANTI-PLAQUE   TOOTHPASTE,   AP-24
ANTI-PLAQUE  MOUTHWASH,  AP-24 TRIPLE  ACTION DENTAL  FLOSS,  AP-24  ANTI-PLAQUE
BREATH SPRAY,  and AP-24 WHITENING  FLUORIDE  TOOTHPASTE.  The AP-24 oral health
care  products  for children are designed to make oral care fun for children and
include JUNGAMAL'S TOUGH TUSK TOOTHPASTE and JUNGAMAL'S FLUFFY FLAMINGO FLOSS.

         Fragrances.  The Company offers a men's and a women's  fragrance  under
the  trademark  SAFIRO.  In 1998,  the Company also  introduced  BELIEVE,  a new
women's fragrance developed with Christie Brinkley.

         Specialty Products.  Epoch is a unique line of ethnobotanical  personal
care  products  created in  cooperation  with well known  ethnobotanists.  These
products,  which  unite  natural  compounds  used by  indigenous  cultures  with
advanced scientific ingredients,  include AVA PUHI SHAMPOO,  GLACIAL MARINE MUD,
DEODORANT WITH CITRISOMES,  POLISHING BAR,  EVERGLIDE  FOAMING SHAVE GEL, DESERT
BREEZE  AFTERSHAVE,  POST SHAVE LOTION FOR WOMEN, and FIREWALKER FOOT CREAM. The
Company also offers a nail care kit.

         NUTRIOL,  a line of  products  licensed  to the Company for sale in the
direct selling channel and  manufactured  in Europe,  consists of five products:
NUTRIOL HAIR FITNESS  PREPARATION,  NUTRIOL SHAMPOO,  NUTRIOL  MASCARA,  NUTRIOL
NAIL, and NUTRIOL  EYELASH.  NUTRIOL  represents a product designed to replenish
the  hair's  vital   minerals   and   elements.   Each   NUTRIOL   product  uses
mucopolysaccharide, a patented ingredient.

         SCION, is a moderately-priced  line of facial care, skin care, and hair
care  products  that was  created  for  less-developed  markets to  address  the
economic  factors in such  markets.  This line was  introduced in several of the
Company's markets in 1998.

         Product Sets.  The Company  currently  offers product sets that provide
samples of products from a given  product line.  These product sets are intended
to encourage increased product trials.

Pharmanex Products

         The Company's  nutritional  supplements are currently distributed under
the brand names Pharmanex and IDN. As the Company integrates  Pharmanex with its
existing nutritional supplement business offerings around the world, the Company
anticipates that certain products currently  distributed under the IDN brand may
be distributed under the Pharmanex brand name. Such a determination will be made
on a  market-by-market  basis as the Company  transitions  to its new divisional
structure.

         The Company's  nutritional  supplements  currently are comprised of its
LIFEPAK  line  of  multi-vitamin  and  mineral  nutritional  supplements,   five
proprietary   natural  nutritional   supplements,   a  broad-line  of  botanical
supplements, and additional nutritional products in the following lines: general
wellness,  weight-management,  nutritious  foods and snacks,  sports and fitness
products, health solutions for people with special needs, and a water filtration
system.  The  Company's  nutritional  products are designed to promote  healthy,
active  lifestyles

                                      -8-

and general well-being through proper diet, exercise,  and nutrition.  In Taiwan
and South Korea,  LIFEPAK is the official  nutritional  supplement of the Taiwan
and South Korea Olympic Committee, respectively.

         Nutritional  products  generally  require  reformulation to satisfy the
strict regulatory requirements of many of the Company's different markets. While
each  product's  concept and  positioning  are  generally  the same,  regulatory
differences  between markets result in some product ingredient  differences.  In
addition,  certain markets, such as Japan, have preferences and regulations that
favor  tablets  instead  of  capsules,  which are  typically  used in the United
States.  Regulatory  requirements in certain markets may restrict the ability of
the Company to introduce  certain  products into such markets.  See  "Government
Regulation - Regulation of Personal Care Products and Nutritional Supplements."

         The  Company's  herbal  supplements  are  standardized,   which  allows
consumers to obtain a specific,  consistent  level of the recommended  dosage of
the important components of the supplement.  Recent studies have found that many
popular herbal  supplements are not standardized and vary enormously in content,
which  correspondingly  varies the effectiveness of the product.  Pharmanex uses
its "6S  Quality  Process"  (Selection,  Sourcing,  Structure,  Standardization,
Safety, and Substantiation) to standardize its botanical supplements to at least
one relevant active  compound and to formulate its non-herbal  products with key
ingredients in amounts designed to enhance the nutritional benefits. The Company
believes  that this 6S Quality  Process  furthers  the ability of the Company to
provide the consumer with safe, effective, and consistent products. See "Product
Development - Pharmanex."

         The following is a brief description of each of the nutritional product
lines within the combined Pharmanex and IDN division:

         General Wellness  Multivitamin/Mineral  Supplements. The LIFEPAK family
of  products,  the core IDN  nutritional  supplement,  is designed to provide an
optimum  mix  of  nutrients  including  vitamins,  minerals,  antioxidants,  and
phytonutrients  (natural  chemical  extracts from plants).  The  introduction of
LIFEPAK in 1994  resulted  in a  significant  increase  in  revenue.  LIFEPAK is
currently  sold in 12 of the Company's  markets,  including  the United  States,
Japan,  and Taiwan.  LIFEPAK is offered in  different  formulations  to meet the
unique needs of women, older adults, and pregnant women.

         Additional   General  Wellness   supplements   include:   VITOX,  which
incorporates beta carotene and other important  vitamins for overall health; and
IMAGE HNS, an all-around  vitamin and  antioxidant  supplement.  THE IDN MASTERS
WELLNESS  SUPPLEMENT  provides  nutrition  specifically for an aging generation.
JUNGAMALS  LIFEPAK FOR KIDS  chewables  combine  natural  flavors and colors and
contain a blend of antioxidants,  chelated minerals,  and vitamins  specifically
tailored for children.  The Company also offers LIFE  ESSENTIALS,  a lower cost,
more general nutritional supplement.

         Pharmanex  Proprietary  Supplements.  Pharmanex  currently  offers five
proprietary natural nutritional  supplements:  CHOLESTIN;  CORDYMAX CS4; TEGREEN
97; ST.  JOHNS';  and BIO GINKGO 27/7.  CHOLESTIN is a  proprietary  nutritional
supplement  derived  from a  proprietary  strain  of red  yeast  rice.  A recent
double-blind,  placebo-controlled  study  conducted at the UCLA Center for Human
Nutrition and  published in the February  1999 issue of the American  Journal of
Clinical  Nutrition  demonstrated  the  effectiveness of CHOLESTIN in helping to
maintain healthy  cholesterol levels. In February 1999, a Federal District Court
judge ruled that  CHOLESTIN  could be legally sold as a  nutritional  supplement
under the Dietary  Supplement  Health and Education Act of 1994  ("DSHEA").  The
Food and Drug  Administration  ("FDA") had  previously  challenged the status of
CHOLESTIN  as a  dietary  supplement,  claiming  it was a drug and  could not be
marketed without FDA approval. There can be no assurance,  however, that the FDA
will not appeal the decision,  and, in the event of an appeal,  that the Company
would be successful in any such appeal. See "Government Regulation -- Regulation
of Personal Care Products and Nutritional Supplements."

                                   -9-

         CORDYMAX CS-4 is a proprietary  nutritional supplement designed to help
reduce  fatigue.  Several  clinical  trials have been  conducted on this product
which have  demonstrated  that  CORDYMAX can help promote  vitality and stamina.
CORDYMAX CS-4 is offered as a stand-alone  product and in a combination  product
with ST. JOHN'S WORT  distributed  under the  trademark BIO ST. JOHNS,  which is
designed to promote  positive  mood and outlook as well as vitality  levels.  In
addition,  the Company also offers BIO GINKGO 27/7, a proprietary  ginkgo biloba
extract that  promotes  blood  circulation  to the brain,  arms,  and legs,  and
TEGREEN 97, a  nutritional  supplement  that  contains a  concentrated  level of
decaffeinated  green tea  polyphenols  that  offer  high  levels of  antioxidant
benefits naturally.

         Pharmanex Broadline Botanicals.  Pharmanex also currently offers a line
of  ten  standardized   botanical  supplements  including  GINSENG,  KAVA  KAVA,
ECHINACEA, GARLIC, and HAWTHORN.  Botanicals can exhibit substantial differences
in content depending on various factors such as season, climate, soil, method of
harvest,  storage,  and  processing.  As a result,  botanical  products can vary
dramatically  in quality and  content.  Pharmanex's  botanical  supplements  are
standardized  to provide  consumers  with a product  that  contains a  specific,
consistent  level of the  desired  dosage  of the  important  components  of the
supplement. In addition, Pharmanex implements quality control processes designed
to enhance the ability of the  Company to keep its  products  pure and free from
insecticides, heavy metals, and other harmful contaminants.

         Nutritious  and Healthy  Snacks.  As part of the  Company's  mission to
promote a healthy lifestyle and long-term wellness, Pharmanex's NUTRI-FOODS line
of products  includes  FIBERRY  FAT-FREE SNACK BARS,  and APPEAL,  a nutritional
drink containing chelated minerals and vitamins. In addition, the Company offers
a number  of other  nutritional  drinks.  SPLASH C with  aloe  vera is a healthy
beverage  providing  significant doses of Vitamins C and E as well as calcium in
each  serving.  Real fruit juice  crystals  are added to create  orange or lemon
flavor.  ALOE-MX,  a nutritional  aloe vera  beverage  drink,  was  specifically
produced for the Japanese and other Asian markets.

         Sports and Fitness Products. Pharmanex's SPORTRITION line of sports and
fitness products caters to health conscious  individuals with active lifestyles.
The line includes the SPORTS  NUTRITION  SYSTEM, a packaged group of nutritional
supplements  offering a  comprehensive,  flexible  program for  individuals  who
desire to optimize  performance.  The system  includes:  LIFEPAK;  OVERDRIVE,  a
sports supplement that features antioxidants,  B vitamins, and chromium chelate;
GLYCOBAR energy bars; and  SPORTALYTE,  a performance  drink  formulated to help
supply the  necessary  carbohydrates,  electrolytes,  and  chelated  minerals to
optimize  performance.  Other  products  in this line  include  AMINO  BUILD,  a
low-fat, high-protein drink mix that is designed to replace nutrients before and
after  workouts,  and  PROGRAM-16  protein  bars, a product  designed to provide
nutritional support for individuals involved in strenuous exercise.

         Health Solutions. Pharmanex products include customized supplementation
addressing the  specialized  interests of health  conscious  individuals.  These
supplements  include:  CARTILAGE  FORMULA,  which  contains an advanced blend of
glucosamine to help maintain  normal  structure and function of healthy  joints;
EYE FORMULA,  which contains  significant levels of beta-carotene and Vitamins C
and E to help  maintain  the normal  structure  and  function  of healthy  eyes;
OPTIMUM  OMEGA,  a pure source of omega 3 fatty  acids;  NIGHTIME  COMPLEX  WITH
MELATONIN,   to  promote  normal  sleep;   FIBRENET  and  FIBRENET  PLUS,  fiber
supplements;  and  NUTRIFI,  a product that  contains  four grams of soluble and
insoluble  fibers per serving in a powder that can be added to liquids and foods
to supplement the recommended daily amounts of fiber.

         HealthTrim 2000. The HEALTHTRIM 2000 weight management program includes
a line of nutritional products designed to provide nutritional support to weight
conscious  individuals  marketed under the following product names:  APPEAL LITE
HT, APPSIGNAL, APPCHOCOLATES, LIFEPAK TRIM, TRIMPAK, METABOTRIM, and BOTANAME.

         Specialty  Products.  In  the  fourth  quarter  of  1998,  the  Company
introduced  a  high-performance  home  water  filtration  system in  Japan.  The
FOUNTAIN  FRESH  filtration  system was  designed  by and is being  manufactured
exclusively for the Company by CUNO  Incorporated,  a worldwide  manufacturer of
home and industrial filtration systems.

                                      -10-

Big Planet Products

         Upon  completion  of the proposed Big Planet  acquisition,  the Company
will add  technology  and  communication  products  and  services to its product
offering.  Big Planet currently provides  technology and communication  products
and services in both standalone and packaged bundles  designed  specifically for
consumers and small businesses who desire a responsive,  single-source  provider
of Internet  connectivity,  communications,  and the ability to purchase on-line
through e-commerce. Big Planet was launched in the United States in April 1998.

         In connection with its products and service  offerings,  Big Planet has
invested   significantly  in  its  Internet  facilities  and  operation  support
facilities.  Big Planet also has entered  into  contractual  relationships  with
several industry-leading  technology companies,  including Qwest Communications,
UUNet,  SkyTel,  IBM, Sun Microsystems and other key vendors, to provide simple,
convenient,  and reliable  technology  products and services through  one-to-one
relationships  provided by the Company's  network of distributors.  Big Planet's
sales representatives  receive commissions based on Big Planet's gross margin on
each sale of products or services,  or based on the  commission  received by Big
Planet with  respect to products  sold  directly by  third-party  vendors to Big
Planet's  customers.  Big  Planet's  products  and services are built around the
following   core   areas:   Internet   services;   telecommunications;   unified
communications; e-commerce; and education.

         Big  Planet's  strategy  has been to combine  the  benefits of a direct
marketing  approach together with the emerging  Internet  opportunity to form an
"InterNetworking"  company that is committed to improving the way people "learn,
communicate,  work,  shop, and play.(TM)" The following  summarizes Big Planet's
current product and service offerings:

         Internet Services. Big Planet provides dial-up Internet services to its
customers  through three separate  access plans designed to cover the needs of a
broad  demographic  group of consumers.  Big Planet  outsources  Internet access
through a  nationwide  telecommunications  network  of over 1,600 dial up access
sites,  or "POPS," in cities  throughout the United States.  Big Planet provides
easy to use,  reliable,  and  competitively  priced Internet access,  electronic
mail, and content  filtration for its sales  representatives  and consumers.  In
October  1998,  Big Planet  introduced  two  Internet  devices;  the IPHONE,  an
innovative  telephone that provides simple and convenient  Internet access via a
phone set; and the  APLIOPHONE,  a device that  connects to the phone and allows
the user to route long-distance calls over the Internet.

         Telecommunications.   Big  Planet   currently   offers   domestic   and
international  long  distance,   prepaid  calling  cards,  paging  products  and
services,  and personal  800 numbers.  Big Planet  offers both  residential  and
business   long  distance   services   through  its   relationship   with  Qwest
Communications.  Big  Planet  also  plans  to offer  wireless  telecommunication
services in the near future through a contract with a wireless service provider.
Big Planet also has a business  relationship with SkyTel which allows Big Planet
to sell SkyTel's prepaid paging products,  including SkyTel's  BEEPWEARPRO pager
watch.

         Unified Communications.  Big Planet currently offers a DYNAMIC WEB PAGE
BUILDER  that  provides  a  powerful,  yet  easy to use tool  for  creating  and
maintaining  sophisticated  Web sites.  DYNAMIC WEB PAGE BUILDER is designed for
small businesses or for a distributor/representative's  personal use. Big Planet
is also exploring the  possibility  and  feasibility of potential  products that
would integrate the Internet and voice-based messaging.

         E-commerce    and    Computing.    The   Big   Planet   on-line   store
(www.bpstore.com)  provides an on-line shopping  environment to Big Planet sales
representatives  and their customers.  The Big Planet store was initially opened
in September  1998 and currently  offers access to a wide  selection of products
and services  from  numerous  different  vendors in addition to Nu Skin Personal
Care and Pharmanex products.  A key focus of the store is on computing products,
including Internet appliances like the IPHONE and the APLIOPHONE. Big Planet has
several  relationships  with other  parties  which links the Big Planet  on-line
store to Web sites such as  OnlineOfficeSupplies.com  and the FlowerCompany.com.
Representatives  earn  commissions on purchases by their  customers  through the
store.

                                      -11-

         Education and Training.  Big Planet offers a variety of educational and
training  products for Big Planet  independent sales  representatives  and their
customers via a combination of the Internet and CD ROM packages.  These products
include  LEARNING  UNIVERSITY,  KIDS EDUCATION  EXCHANGE,  children  multi-media
education  products,   the  INTERACTIVE   ACHIEVEMENT  CENTER,  the  WORLD  BOOK
ENCYCLOPEDIA, and the LEARNING CENTER. Sales Aids

         The Company  provides an  assortment  of sales aids to  facilitate  the
sales of its  products.  Sales aids include  videotapes,  promotional  clothing,
pens,  stationery,  business cards,  brushes,  combs, cotton pads, tissues,  and
other  miscellaneous  items to help create consumer awareness of the Company and
its  products.  Sales aids are priced at the  Company's  approximate  cost,  and
distributors do not receive commissions on purchases of sales aids.

Product Guarantees

         The  Company  believes  that it is among  the most  consumer-protective
companies in the direct selling industry. For 30 days from the date of purchase,
the Company's  product  return  policy  allows a retail  purchaser to return any
product to the  distributor  through whom the product was  purchased  for a full
refund. After 30 days from the date of purchase,  the return privilege is in the
discretion  of the  distributor.  Because  distributors  may  return  unused and
resalable  products to the Company for a refund of 90% of the purchase price for
one year,  they are  encouraged to provide  consumer  refunds beyond 30 days. In
addition,  the  product  return  policy is a material  aspect of the  success of
distributors in developing a retail customer base. The Company's experience with
actual  product  returns has averaged less than 3.5% of annual  revenue  through
1998.  Because many of Big Planet's  products and services are provided directly
to consumers by third-party  vendors,  the same 30-day return privilege does not
apply to products  purchased by consumers  from such vendors unless such vendors
otherwise agree.

Distribution System

         Overview of Distribution  System. The foundation of the Company's sales
philosophy  and  distribution  system is network  marketing.  Under most network
marketing  systems,  distributors  purchase products for resale to consumers and
for personal  consumption.  Pursuant to the Company's Global  Compensation Plan,
products are sold exclusively to or through independent distributors who are not
employees  of the  Company.  Because of the nature of the  products and services
provided by Big Planet,  Big Planet  distributors do not buy products for resale
but act as independent sales  representatives of Big Planet.  Under most network
marketing systems, independent distributors purchase products for resale and for
personal consumption.

         Network  marketing is an effective  vehicle to distribute the Company's
products because:

       *      A  consumer  can be  educated  about  a  product  in  person  by a
              distributor,  which the Company  believes is more  effective  than
              using television and print advertisements;

       *      Direct  sales  allow for actual  product  testing  by a  potential
              consumer;

       *      The impact of distributor  and consumer  testimonials is enhanced;
              and

       *      As compared to other distribution  methods,  distributors can give
              customers higher levels of service and attention,  by, among other
              things,  delivering  products directly to a consumer and following
              up  on  sales  to  ensure   proper   product  usage  and  customer
              satisfaction, and to encourage repeat purchases.

         Direct selling as a distribution  channel has been enhanced in the past
decade due to advancements in communications,  including  telecommunications and
Internet  connectivity,  and  the  proliferation  of the use of  videos  and fax
machines. Direct selling companies rely on telecommunications, the Internet, and
videos to project a

                                      -12-

desired image for such companies and their product lines.  The Company  believes
that  high  quality  sales  aids  play  an  important  role  in the  success  of
distributor efforts. For this reason, the Company maintains an in-house staff of
video production  personnel and video and audio cassette  duplication  equipment
for timely and cost-effective  production of sales materials.  In addition,  the
Company intends to leverage the expertise of Big Planet management following the
completion  of the  proposed  Big  Planet  acquisition  to  implement  effective
Internet  strategies in each of the  Company's  product  divisions.  The Company
believes that the Internet will become an increasingly important business factor
as more and more  consumers  purchase  products  over the Internet as opposed to
traditional  retail and direct sales channels.  As a result, the Company expects
that direct  sellers will need to adapt their  business  models to integrate the
Internet into their operations to remain successful.  Management is committed to
fully utilizing current and future technological  advances to continue enhancing
the  effectiveness  of direct  selling.  See "Risk Factors -- "Risks  Related to
Potential Changes in Business Model."

         The Company's network marketing program differs from many other network
marketing  programs in several respects.  First, the Company was among the first
to  develop  the  ability  for  distributors  to be  compensated  in their  home
countries for sales across the globe.  The Company's  Global  Compensation  Plan
allows  Company  distributors  to develop a seamless  global network of downline
distributors.  Second, the Company's order and fulfillment systems eliminate the
need for  distributors  to carry  significant  levels of inventory.  Third,  the
Global  Compensation Plan is among the most financially  rewarding plans offered
to distributors by network marketing companies, and can result in commissions to
distributors  aggregating up to 58% of a product's  wholesale price. On a global
basis,  commissions  have  averaged  approximately  39 to  41% of  revenue  from
commissionable  sales  over  the  last  eight  years.  Big  Planet  does not pay
commissions  on the  wholesale  price but on the  gross  margins  from  sales of
services  and  products.  If products and  services  are  purchased  directly by
distributors or customers from third parties with contractual relationships with
Big Planet,  the  commission  is based on the total  commission  that Big Planet
receives  from such  third  parties  with  respect to such  sales.  Accordingly,
commissions  paid with respect to Big Planet products and services would be less
as a percentage of revenue than the Company's historic commission levels.

         In  connection  with the  proposed  acquisition  of Big  Planet and the
Company's decision to shift to a divisional  structure,  the Global Compensation
Plan will be  re-engineered  to allow  distributors to develop a seamless global
network of downline  distributors across any or all of the Company's  divisions.
Currently,  distributors  can be  compensated  to some degree for sales in other
divisions. The Company,  however, intends to modify the Global Compensation Plan
to simplify this process and increase the ability of  distributors  to develop a
network of downline  distributors  across  divisions.  The Company believes this
will benefit the Company by allowing distributors to focus on one division while
still being  eligible to be  compensated  for sales  generated by their downline
distributors in other divisions. By developing a compensation plan and structure
that does not penalize a distributor for focusing on one division,  distributors
will be better able to develop  expertise in an area of interest to them,  which
should allow them to provide a greater level of service.  This structure  should
also promote  cross-selling  by  distributors  across  divisions as they recruit
downline members with differing interests because they will still be compensated
for  sales  generated  by  such  downline  members.   The  re-engineered  Global
Compensation  Plan will be the same  essentially  as the existing  plan to avoid
confusion, but the structure for commissions on the front-end of the plan (i.e.,
sales by distributors to its direct  customers) may be modified for a particular
product division.

         The   Company's   revenue   depends   directly   upon  the  efforts  of
distributors. Growth in sales volume requires an increase in the productivity of
distributors and/or growth in the total number of distributors.  There can be no
assurance that the  productivity or number of distributors  will be sustained at
current  levels or increased in the future.  See "Risk  Factors -- Reliance upon
Independent  Distributors."  Furthermore,  the  Company  estimates  that,  as of
December  31,  1998,  approximately  300  distributorships  worldwide  comprised
Hawaiian Blue Diamond and Blue Diamond executive  distributor levels,  which are
the Company's two highest executive  distributor levels and, together with their
extensive  downline  networks,  account for  substantially  all of the Company's
revenue.  Consequently, the loss of such a high-level distributor or another key
distributor, together

                                      -13-

with a group of leading distributors in such distributor's  downline network, or
the loss of a significant number of distributors for any reason, could adversely
affect the Company's results of operations.

         Sponsoring.  The  Company  relies on its  distributors  to sponsor  new
distributors.  While the Company provides, at cost, product samples,  brochures,
magazines, and other sales materials, distributors are primarily
responsible for educating new distributors with respect to products,  the Global
Compensation  Plan,  and how to build a  successful  distributorship.  See "Risk
Factors - Reliance upon Independent Distributors."

         The  sponsoring  of new  distributors  creates  multiple  levels in the
network marketing structure. Persons whom a distributor sponsors are referred to
as "downline" or "sponsored" distributors. If downline distributors also sponsor
new  distributors,  they create  additional  levels in the structure,  but their
downline  distributors  remain in the same  downline  network as their  original
sponsoring distributor.

         Sponsoring  activities  are  not  required  of  distributors.  However,
because of the financial  incentives provided to those who succeed in building a
distributor  network that consumes and resells  products,  the Company  believes
that most of its  distributors  attempt,  with  varying  degrees  of effort  and
success,  to sponsor additional  distributors.  Generally,  distributors  invite
friends,  family members,  and  acquaintances to sales meetings in which Company
products are presented and the Global Compensation Plan is explained. People are
often attracted to become distributors after using Company products and becoming
regular retail customers. Once a person becomes a distributor, he or she is able
to purchase products directly from the Company at wholesale prices for resale to
consumers or for  personal  consumption.  The  distributor  is also  entitled to
sponsor  other  distributors  in order to build a network  of  distributors  and
product users.

         A  potential   distributor  must  enter  into  a  standard  distributor
agreement  with the Company  which  obligates  the  distributor  to abide by the
Company's policies and procedures.  Additionally, in all countries except Japan,
a new  distributor is required to enter into a product  purchase  agreement with
the Company's local subsidiary,  which governs product purchases.  In certain of
the Company's markets, distributors are also required to purchase a starter kit,
which  includes  the  Company's  policies  and  procedures  and are sold for the
approximate cost of producing the starter kit.

         Global Compensation Plan. Management believes that one of the Company's
key competitive advantages is the Global Compensation Plan. Distributors receive
higher levels of commissions as they advance under the Global Compensation Plan.
The Global  Compensation  Plan is  seamlessly  integrated  across all markets in
which the Company's personal care products,  nutritional  supplements,  and upon
completion of the proposed  acquisition of Big Planet, Big Planet's products and
services,  are sold,  allowing  distributors  to receive  commissions for global
product sales, rather than merely local product sales. This seamless integration
means  that  the  Company's  distributor  base  has  global  reach  and that the
knowledge  and  experience  of  current   distributors  can  be  used  to  build
distributor  leadership  in new markets.  The Global  Compensation  Plan will be
modified in  connection  with the Company's  shift to a divisional  structure to
seamlessly integrate it across all divisions.

         Allowing distributors to receive commissions at the same rate for sales
in foreign  countries as for sales in their respective home countries and across
each division is a significant  benefit to  distributors.  Distributors  benefit
from this because they are not required to  establish  new  distributorships  or
requalify for higher levels of commissions within each new country in which they
begin to operate or in each new division, which is frequently the case under the
compensation plans of the Company's major competitors. Under the modified Global
Compensation Plan, a distributor will be paid consolidated  monthly  commissions
in the distributor's home country, in local currency,  for product sales in that
distributor's global downline distributor network across all divisions.

         High  Level of  Distributor  Incentives.  Based upon its  knowledge  of
distributor   compensation   plans,   the  Company   believes  that  the  Global
Compensation  Plan is among the most  financially  rewarding  plans  offered  to
distributors by network marketing  companies.  There are two fundamental ways in
which  distributors  can earn

                                      -14-

money: (i) through retail markups, for which the Company recommends a range from
43% to 60%; and (ii) through a series of commissions on product sales, which can
result in  commissions  to  distributors  aggregating  up to 58% of a  product's
wholesale  price.  On  a  global  basis,  however,   commissions  have  averaged
approximately 39 to 41% of revenue from commissionable sales over the last eight
years.  Because Big Planet pays  commissions  on the gross margins from sales of
services  and  products,  or on  commissions  received  by Big Planet from third
parties  with  respect  to sales  from such  third  parties,  as  opposed to the
wholesale  price,  the commissions  paid with respect to Big Planet products and
services  would be less as a percentage of revenue than the  Company's  historic
commission levels.

         Each  product  carries  a  specified  number  of sales  volume  points.
Commissions are based on total personal and group sales volume points per month.
Sales volume points are essentially  based upon a product's  wholesale cost, net
of any point-of-sale taxes. As a distributor's retail business expands and as he
or she successfully  sponsors other  distributors  into the business who in turn
expand  their  own  businesses,  he or  she  receives  a  higher  percentage  of
commissions.

         Once a distributor  becomes an executive,  the distributor can begin to
take full advantage of the benefits of commission payments on personal and group
sales  volume.  To  achieve  executive  status,  a  distributor  must  submit  a
qualifying  letter of intent and  achieve  specified  personal  and group  sales
volumes  for a  four-month  period of time.  To  maintain  executive  status,  a
distributor  must  generally  also maintain  specified  personal and group sales
volumes for a two-to-four  month period.  An  executive's  commissions  increase
substantially as multiple  downline  distributors  achieve  executive status. In
determining commissions,  the number of levels of downline distributors that can
be  included  in an  executive's  group  increases  as the  number of  executive
distributorship directly below the executive increases.

         As of the dates indicated  below,  the Company had the following number
of executive distributors.

                     Total Number of Executive Distributors

                                              As of December 31,
                               -------------------------------------------------
 Executive Distributors        1994       1995       1996       1997       1998
 ------------------------     ------     ------     ------     ------     ------
 North Asia .............      3,613      4,017     14,844     16,654     17,311
 Southeast Asia .........      2,778      4,129      6,199      5,642      5,091
 Other Markets ..........         --         27        436        393        379
                              ------     ------     ------     ------     ------
 Total ..................      6,391      8,173     21,479     22,689     22,781
                              ======     ======     ======     ======     ======

         On a monthly basis,  the Company  evaluates  requests for exceptions to
the  Global  Compensation  Plan.  While  the  general  policy  is to  discourage
exceptions, management believes that the flexibility to grant such exceptions is
critical in  retaining  distributor  loyalty  and  dedication.  In each  market,
distributor  services personnel evaluate each such instance and make appropriate
recommendations to the Company.

         Distributor  Support.  The Company is committed to providing high-level
support services  tailored to the needs of its distributors in each market.  The
Company  meets  the  needs and  builds  the  loyalty  of its  distributors  with
personalized  distributor  service, a support staff that assists distributors as
they build  networks  of downline  distributors,  and a liberal  product  return
policy.  Because many distributors have only a limited number of hours each week
to concentrate on their Nu Skin business,  management believes that maximizing a
distributor's efforts through effective support of each distributor has been and
will continue to be important to the success of the Company.

                                      -15-

         Through  training  meetings,  annual  conventions,   distributor  focus
groups,   regular  telephone   conference  calls,  and  personal  contacts  with
distributors,  the  Company  seeks to  understand  and satisfy the needs of each
distributor.  The Company provides walk-in, telephonic, and computerized product
fulfillment and tracking services that result in  user-friendly,  timely product
distribution.  In addition,  the Company is committed to evaluating new ideas in
technology and services, such as automatic product reordering,  that the Company
can  provide  to  distributors.   The  Company  currently  utilizes   voicemail,
teleconferencing,  and fax services.  Global Internet access (including  Company
and product information, ordering abilities, and group and personal sales volume
inquiries) is anticipated  to be provided to  distributors  in the future.  Each
walk-in  center  maintains  meeting  rooms  which  distributors  may  utilize in
training and sponsoring activities.

         Rules  Affecting  Distributors.   The  Company's  standard  distributor
agreement,  policies and procedures,  and  compensation  plan contained in every
starter and/or  introductory  kit outline the scope of  permissible  distributor
marketing  activities.  The  Company's  distributor  rules  and  guidelines  are
designed to provide distributors with maximum flexibility and opportunity within
the bounds of governmental  regulations  regarding network marketing and prudent
business policies and procedures.  Distributors are independent  contractors and
are thus prohibited from  representing  themselves as agents or employees of the
Company.  Distributors  are  obligated  to present the  Company's  products  and
business opportunity  ethically and professionally.  Distributors agree that the
presentation of the Company's business  opportunity must be consistent with, and
limited  to,  the  product  claims  and   representations   made  in  literature
distributed  by  the  Company.  Under  most  regulations  governing  nutritional
supplements,  no medical  claims may be made  regarding  the  products,  nor may
distributors  prescribe  any  particular  product as suitable  for any  specific
ailment.  Even though sponsoring  activities can be conducted in many countries,
distributors  are prohibited from  conducting  marketing  activities  outside of
countries in which the Company  conducts  business and are not allowed to export
products  from one  country  to  another.  See "Risk  Factors --  Reliance  upon
Independent Distributors."

         Distributors must represent that the receipt of commissions is based on
retail sales and substantial efforts. Exhibiting commission statements or checks
is  prohibited.  Sales  aids such as  videotapes,  promotional  clothing,  pens,
stationery,  and other  miscellaneous  items must be produced or pre-approved by
the Company.

         Distributors  may not use any  form of  media  advertising  to  promote
products.  Products may be promoted  only by personal  contact or by  literature
produced or approved by the Company. Generic business opportunity advertisements
(without  using the  Company  name) may be placed  in  accordance  with  certain
guidelines  in  some  countries.  The  Company's  logos  and  names  may  not be
permanently  displayed  on  physical  premises.  Distributors  may  not  use the
Company's  trademarks  or other  intellectual  property  without  the  Company's
consent.

         Products  generally may not be sold, and the business  opportunity  may
not be promoted,  in  traditional  retail  environments.  Pharmanex  has made an
exception  to this rule for its  nutritional  supplements  and has allowed  such
products to be sold in  independently-owned  pharmacies  and drug stores meeting
certain  requirements.  Additionally,  distributors may not sell at conventions,
trade shows, flea markets, swap meets, and similar events.  Distributors who own
or are employed by a  service-related  business such as a doctor's office,  hair
salon, or health club, may make products  available to regular customers as long
as products are not displayed  visibly to the general public in such a way as to
attract the general public into the establishment to purchase products.

         Generally,  a distributor can receive  commission bonuses only if, on a
monthly basis, (i) the distributor  achieves at least 100 points  (approximately
$100) in personal sales volume,  (ii) the distributor  documents retail sales to
at least five retail  customers,  (iii) the distributor sells and/or consumes at
least 80% of personal sales volume,  and (iv) the  distributor is not in default
of any material policies or procedures.

         The  Company  systematically  reviews  alleged  reports of  distributor
misbehavior.  If the Company  determines  that a distributor has violated any of
the   distributor   policies  or  procedures,   it  may  either   terminate  the
distributor's rights completely or impose sanctions such as warnings, probation,
withdrawal or denial of an award, suspension of privileges of a distributorship,
fines or penalties,  withholding  commissions  until  specified  conditions

                                      -16-

are satisfied, or other appropriate injunctive relief.  Distributor terminations
based on violations of the Company's  policies and  procedures  have  aggregated
less than 1.0% of the Company's distributor force since inception. A distributor
may voluntarily terminate his/her distributorship at any time.

         Payment.  Distributors  generally  pay for products  prior to shipment.
Accordingly,  the Company  carries  minimal  accounts  receivable.  Distributors
typically pay for products in cash, by wire transfer, and by credit
cards. Cash, which represents a significant portion of all payments, is received
by order takers in the distribution centers when orders are personally picked up
by a distributor.

Product Development

         The Company is committed to building its brand name and distributor and
customer loyalty by selling premium quality,  innovative  personal care products
and nutritional  supplements that appeal to broad markets. The Company's product
philosophy  is to combine  the best of science and nature and to include in each
of its  products the highest  quality  ingredients  with the greatest  amount of
benefit to the consumer.  Independent  distributors need to have confidence that
they are distributing the best products available that are distinguishable  from
"off the shelf"  products.  The Company is committed to developing and providing
quality  products  that can be sold at  attractive  retail  prices and allow the
Company to maintain reasonable profit margins.

         The Company  believes that timely and strategic  product  introductions
are critical to  maintaining  the growth of independent  distribution  channels.
Distributors become enthusiastic about new products and are generally excited to
share new products with their customer base. An expanding  product line helps to
attract new distributors and generate additional revenues.

         Nu Skin Personal Care. The  development  philosophy of the Company with
respect to its  personal  care  products is  represented  by its  personal  care
products  slogan  "All of the Good and None of the Bad." Nu Skin  personal  care
products  do not  contain  soaps  and  other  harsh  cleansers  that can dry and
irritate skin, undesirable oils such as lanolin, elements known to be irritating
and pore  clogging,  and  conditioning  agents  that leave heavy  residues.  The
Company is also  committed to constantly  improving  its evolving  personal care
product  formulations to incorporate  innovative and proven ingredients into its
product line. Whereas many consumer product companies develop a formula and stay
with that formula for years, and sometimes decades, the Company believes that it
must stay  current  with  product  and  ingredient  evolution  to  maintain  its
reputation  for  innovation  to retain  distributor  and consumer  attention and
enthusiasm.  For this reason, the Company continuously evaluates its entire line
of products for possible enhancements and improvements.

         Nu  Skin  Personal  Care   maintains  a  laboratory   and  a  staff  of
approximately 40 individuals involved in personal care product development.  The
Company also relies on an advisory board comprised of recognized  authorities in
various   disciplines.   The   Company   recently   entered   into  a  nine-year
directed-research  agreement  to form  the Nu  Skin  Center  for  Dermatological
Research with Stanford  University  Medical  Center's  Department of Dermatology
pursuant to which the Company will direct  research  and  clinical  trials of Nu
Skin products or materials.  The Company also evaluates a significant  number of
product ideas that are  presented by  distributors,  vendors,  and other outside
sources. The Company believes that strategic  relationships with certain vendors
provides important access to innovative product concepts. The Company intends to
continue to develop  products  tailored to appeal to the particular needs of the
Company's markets.

         Pharmanex. From the date it first decided to begin offering nutritional
products,  the Company has been committed to providing high quality  nutritional
supplements,  as typified by the  Company's  best selling  nutritional  product,
LIFEPAK. This philosophy has led to the Company's commitment to avoid stimulants
and any ingredients that are reported to have any long-term addictive or harmful
effects,  even  if  the  short-term  effects  may  be  desirable.   Through  the
acquisition of Pharmanex,  the Company believes that its increased  research and
development  capabilities  will  solidify  the  Company  as one of the  industry
leaders in  developing  and  distributing  high-grade,  clinically-substantiated
nutritional  supplements.  The  Company  believes  that  it is one  of  the  few

                                      -17-

nutritional  supplement  companies in the United  States that has a research and
development department patterned after the pharmaceutical  industry and believes
that this research and  development  capability will provide the Company with an
important   competitive  advantage  in  this  industry.   Moreover,   because  a
substantial portion of its research and development  activities are conducted in
China,  the Company  believes that it should be able to conduct quality research
and development  work as well as initial  clinical trials at costs that are less
than would be incurred if conducting comparable work in the United States.

         In its development of natural and botanical supplements,  the Company's
primary  research and  development  goal is to selectively  develop  proprietary
technologies   for  the   purification   and   standardization   of  efficacious
"single-species"   herbal  products.   Selection  of  a   botanical/natural   or
nutritional  product  for  development  is based on  available  scientific  data
concerning  safety and efficacy and consumer need. The Company  utilizes its "6S
Quality Process" (Selection, Sourcing, Structure,  Standardization,  Safety, and
Substantiation) in its development and sourcing  activities,  which are designed
to  provide a  precise,  standardized,  recommended  dosage  of each  beneficial
natural ingredient in every capsule. The "6S Quality Process" generally involves
the following actions:

       *      Selection.   Conducting  a  scientific   review  of  research  and
              databases in connection  with the selection of potential  products
              and ingredients, and determining the authenticity, usefulness, and
              safety standards for such potential products and ingredients.

       *      Sourcing.  Investigating potential sources, evaluating the quality
              of such sources, and performing botanical and chemical evaluations
              where appropriate.

       *      Structure.   Determining   the  structural   analyses  of  natural
              compounds and active ingredients.

       *      Standardization.   Standardizing  the  product  to  at  least  one
              relative active ingredient.

       *      Safety.  Assessing  safety from  available  research,  and,  where
              necessary, performing additional tests such as microbial tests and
              chemical, toxin, and heavy metal analyses.

       *      Substantiation.  Reviewing  documented  pre-clinical  and clinical
              trials,  and where necessary and appropriate,  initiating  studies
              and clinical trials sponsored by the Company.

         The Company employs approximately 50 M.D. and Ph.D.-level scientists at
its dedicated  research and development  center in Shanghai,  China,  and at its
Provo, Utah and San Francisco, California offices. The Company also relies on an
advisory  board   comprised  of  recognized   authorities  in  various   related
disciplines.  In addition, the Company evaluates a significant number of product
ideas that are presented by distributors and other outside sources.  The Company
believes  that  strategic   relationships  with  certain  vendors  also  provide
important  access to innovative  product  concepts.  The Company has established
collaborative   agreements  with  four  established  universities  and  research
institutions in China: Shanghai Medical University,  Beijing Medical University,
Institute  of Materia  Medica,  and National  Laboratory  of  Contraceptive  and
Devices  Research.  The  staff  of each  institution  includes  scientists  with
expertise in natural product chemistry, biochemistry, pharmacology, and clinical
studies.  Collaborative efforts with these institutions are coordinated with and
validated by the  Company's  Research and  Development  Center in Shanghai.  The
Company also  currently has  collaborative  research and clinical study programs
with several major university  research centers in the United States,  including
UCLA, Tufts University,  Columbia University, Kansas University, and the Scripps
Institute.

         Big Planet.  To date, Big Planet's  product  development has focused on
developing its Internet  facilities and operational  systems in order to develop
operational and support platforms necessary to ensure consistent introduction of
new products and  services,  which Big Planet  believes is necessary to maintain
excitement among sales representatives.  Big Planet seeks to identify and secure
contractual  relationships  with various  vendors and suppliers that will enable
Big Planet to sell competitively-priced technology products and services through
its distribution  channel.  In addition,  Big Planet is committed to identifying
and securing contractual  relationships with various vendors and suppliers for a
wide selection of products for sale through its on-line store.

                                      -18-

Substantially  all  of  the  Company's   products  and  services  are  currently
contracted from third parties. See "Sourcing and Production - Big Planet."

Sourcing and Production

         Virtually all of the Company's  personal care and nutritional  products
are  currently  produced  by  manufacturers  unaffiliated  with the  Company  in
accordance  with  specifications  provided by the Company or  developed  by such
manufacturers for the Company.  The Company's profit margins, and its ability to
deliver its existing  products on a timely basis, are dependent upon the ability
of these outside  manufacturers  to continue to supply  products in a timely and
cost-efficient manner.  Furthermore,  the Company's ability to enter new markets
and sustain satisfactory levels of sales in each market depends in part upon the
ability of suitable outside  manufacturers to reformulate existing products,  if
necessary  to  comply  with  local  regulations  or  market  environments,   for
introduction  into such markets.  Finally,  the  development  of additional  new
products in the future will likewise  depend in part on the services of suitable
outside  manufacturers.  The Company has been shifting some of its manufacturing
of products to its foreign  markets in order to protect its gross margins during
fluctuations  in  currency  exchange  rates.  For  example,  in 1998 the Company
contracted  to have LIFEPAK (for Taiwan)  manufactured  locally in the Taiwanese
market.

         Nu Skin  Personal  Care.  The Company  currently  acquires  products or
ingredients for its personal care products from sole suppliers or suppliers that
are considered by the Company to be the superior  suppliers of such ingredients.
The Company currently relies on one unaffiliated  supplier for approximately 50%
of its personal care products. The Company's contract with this supplier expires
at the end of 2000.  The  Company  believes  that,  in the event it is unable to
source any products or ingredients from this supplier, the Company could produce
such products or replace such products or substitute  ingredients  without great
difficulty or prohibitive  increases in the cost of goods sold.  However,  there
can be no  assurance  that the loss of this  supplier  would not have a material
adverse effect on the Company's  business and results of  operations.  See "Risk
Factors -- Reliance on Limited Suppliers."

         Pharmanex.  Substantially all of the Company's nutritional  supplements
and  ingredients,  including  LIFEPAK,  are produced or provided by  third-party
suppliers  that are  considered  by the Company to be the superior  suppliers of
such  products  and/or   ingredients.   The  Company  currently  relies  on  one
unaffiliated supplier for approximately 30% of its nutritional supplements.  The
Company  believes  that,  in the event it is unable to source  any  products  or
ingredients  from this  supplier or its other current  suppliers  other than set
forth below, the Company could produce such products or replace such products or
substitute  ingredients without great difficulty or prohibitive increases in the
cost of goods sold. However, there can be no assurance that the loss any of such
suppliers would not have a material adverse effect on the Company's business and
results of operations. In addition, one of the Company's proprietary nutritional
supplements,  CordyMax  Cs4, is sourced or licensed from a sole supplier of such
product in China pursuant to a ten-year contract.  CHOLESTIN is sourced from two
different  suppliers  pursuant to  contracts  that expire in 2008 and 2016.  The
CHOLESTIN and CordyMax  agreements have minimum  purchase  requirements.  In the
event the Company fails to satisfy these minium purchase  requirements,  it will
be  required  to pay a penalty.  In  addition,  the Company is required to pay a
termination  fee if its wants to terminate  the  agreements  prior to the end of
their  respective  terms.  In the event the Company is unable to source products
from these suppliers,  the Company could have difficulty  finding another source
of these products. See "Risk Factors - Reliance on Limited Suppliers."

         As part of the  acquisition  of  Pharmanex,  the  Company  acquired  an
extraction and purification facility located in Huzhou, Zhejiang Province, China
where it currently  produces the extracts for its BIOGINKO 27/7 and TEGREEN 97
products and also a certain potential new product.

         The  Company  has  focused  on a  five-step  sourcing  process  for its
proprietary natural supplements,  such as CHOLESTIN and BIO GINKO 27/7 to ensure
product  quality.  The first step in this  process is to identify the sources of
raw material  from among many  different  species.  This requires the Company to
employ or engage the

                                      -19-

necessary  botanical expertise to identify the species required for a particular
product.  The second step involves  evaluating the raw material's  availability.
The  Company  focuses  on  products  that  utilize  raw  materials  that  can be
cultivated in quantities  sufficient to produce satisfactory  yields.  Variables
such as location,  seasonal  availability,  stability,  access,  and alternative
sources must e considered.  Once the sources of supply have been identified, the
third step is to evaluate their quality--which can differ significantly not just
by source,  but by time of harvest and method of harvest.  The Company has found
that steps two and three require an  on-the-ground  presence and local expertise
to be done  properly.  Step four is to identify the source of supply.  To ensure
raw material supply, the Company may engage in both forward contracts as well as
contracts  with multiple  suppliers.  As a final step to ensuring  quality,  the
Company,  when possible,  physically  supervises the harvest and shipment of all
raw materials and bulk extract purchased. This activity involves not only visual
inspection,  but also chemical analysis of the level of active ingredient in the
material at the harvest site and at the receiving dock.

         The  Company  has  contract  cultivation  areas in China  and in Chile.
Because  certain of its  botanical  products such as ST. JOHNS WORT and BIOGINKO
27/7 come from crops that can only be harvested once a year,  problems with such
crops could limit the ability of the Company to produce products associated with
that plant species  during a poor harvest year. In addition,  as these  products
can only be produced  once a year,  the Company must rely on the accuracy of its
estimates of its product requirements in sourcing these products. If the Company
underestimates  its product  requirements,  it may not be able to re-stock  such
product until the next growing season.  In order to help alleviate this problem,
the  Company is working on  sourcing  raw  materials  in both the  Northern  and
Southern  hemisphere  to provide for two  separate  growing  seasons.  See "Risk
Factors -- Reliance on Limited Suppliers."

         Big Planet.  Substantially  all of the services and products offered by
Big Planet currently are contracted from unaffiliated  third parties pursuant to
contractual  arrangements.  For example,  Big Planet has  contracted  with Qwest
Communications  to provide  long  distance  phone  services  for the Company and
contracted  with UUNET for  dial-up  access.  By acting as a  reseller  of these
services,  Big  Planet  is  able to  avoid  the  large  capital  deployment  and
investment  that would be required to build the  infrastructure  to provide such
services  itself until such time as it has developed a sufficient  customer base
to make  investments  in  infrastructure  and equipment  economically  feasible.
However,  Big Planet's profit margins and its ability to deliver quality service
at  competitive  prices are dependent upon its ability to negotiate and maintain
favorable terms with such third-party providers.  Big Planet also contracts with
or enters into various business  relationships with various unaffiliated parties
to acquire the right to distribute unique and innovative  products,  such as the
i-Phone through its e-commerce services.

         Big  Planet,  however,  has  invested  significantly  in  its  Internet
facilities and customer support in order to add value and  differentiate  itself
in the market place. Additionally, implementation of operational support systems
allows Big Planet to own the  complete  relationship  with the  customer,  which
enhances the Company's  ability to retain  customers and market  additional  new
products and services.

Regional Profiles

         For  information  on the Company's  revenue for each of the  geographic
regions in which the Company  operated  for the years ended  December  31, 1996,
1997, and 1998 and other related information, reference is made to "Management's
Discussion and Analysis of Financial  Condition and Results of Operations,"  and
Note 16 to the Company's  Consolidated  Financial Statements,  each of which are
incorporated  herein  by  reference  to the  Company's  1998  Annual  Report  to
Stockholders, sections of which are filed herewith as Exhibit 13.

         North Asia. The Company's North Asia region  currently  consists of its
markets in Japan and South Korea.  Japan is the  Company's  largest  market with
approximately  $654.2  million  in  revenue  in  1998.  According  to the  World
Federation of Direct Selling Associations ("WFDSA"),  the direct selling channel
in Japan generated sales of  approximately  $30 billion of goods and services in
1997,  making Japan the largest direct  selling market in the world.  Management
believes  that as many as six  million  people are  involved  in direct  selling
businesses  in  Japan.   Direct  selling  is  governed  by  detailed  government
regulation  in Japan.  See "Risk  Factors  --  Government

                                      -20-

Regulation of Direct Selling  Activities." The Company's  success to date can be
directly  attributed  to the growth of its  Japanese  business in recent  years.
While  the  direct  sales  market as a whole has  remained  relatively  flat for
several years in Japan, the Company has posted  double-digit  growth in revenue,
on a local currency  basis,  each year since the Company  entered this market in
1993.

         As of December  31,  1998,  the Company  offered 94 of its 116 personal
care products and 19 of its 62 nutritional  supplements,  including  LIFEPAK and
LIFEPAK Trim, the Company's core nutritional  supplements.  In addition,  in the
fourth  quarter of 1998,  the Company also  introduced  a home water  filtration
system  designed  for the  Japanese  market.  With a suggested  retail  price of
approximately  $400,  this  is  the  Company's  first  large-ticket  item  to be
distributed  through its  channel.  The Company  currently  offers 59 of its 116
personal care products and six of its 62 nutritional supplements in South Korea.
The Company has not introduced any of the proprietary natural health supplements
or botanical  supplements  acquired in connection with the recent acquisition of
Pharmanex  such as CHOLESTIN  and CordyMax  Cs-4 in either Japan or South Korea.
Subject to obtaining all necessary regulatory  approvals and registrations,  the
Company plans to begin to introduce certain of the Pharmanex  botanical products
into Japan and South Korea  sometime in the second or third quarter of 1999. See
"Risk Factors -- Government Regulation of Personal Care Products and Nutritional
Supplements."

         Southeast Asia. The Company's  Southeast Asia region currently consists
of its markets in Taiwan, Hong Kong, Thailand, the Philippines, New Zealand, and
Australia.  This region has been  significantly  affected by the Asian  economic
crisis,  which  has  severely  curtailed  consumer  spending,   particularly  in
Thailand.  See  "Risk  Factors  --  Economic  and  Political  Conditions  in the
Company's Markets."

         Taiwan is the largest  market in this  region  with  revenue of $ 119.5
million in 1998.  According to the WFDSA,  the direct selling  channel in Taiwan
generated  approximately $1.7 billion in sales of goods and services in 1996, of
which approximately 43% were nutritional products.  Management believes that the
direct selling  industry in Taiwan  contracted  during 1998. The contraction was
more  significant  in United  States  dollar terms as a result of the  weakening
Taiwanese  dollar.  Approximately two million people  (approximately  10% of the
population)  are  estimated  to be involved in direct  selling.  Because a large
percentage  of its  population  is involved in direct  selling  activities,  the
Taiwan government  regulates direct selling activities to a significant  extent.
For example, the Taiwan government has enacted tax legislation aimed at ensuring
proper tax payments by  distributors on their  transactions  with end consumers.
See "Risk Factors -- Government  Regulations of Direct Selling  Activities." The
Company  believes  that it is one of the largest  direct  selling  companies  in
Taiwan. As of December 31, 1998, the Company offered 94 of its 116 personal care
products and 17of its 62 nutritional supplements in Taiwan.

         Other  Countries.   The  Company's  Other  Countries  region  currently
consists  of the  Company's  13 markets in Europe,  Brazil,  and United  States,
which,  until March 1999, had been operated by private  affiliates.  See "Recent
Developments." The European markets first opened in 1995 with the opening of the
United  Kingdom,  Belgium,  the  Netherlands,  France,  and Germany.  Since that
initial  opening,  an  additional  eight  markets  have been  opened in  Europe,
including Sweden, Denmark, and Poland in 1998. Approximately 75 of the Company's
personal care products are sold in Europe.  The Company has introduced  three to
five of its IDN  products  in a liminted  number of its  European  markets.  The
Company believes the nutritional supplement market provides the Company with its
greatest growth  potential in Europe.  The Company recently hired a new European
vice  president  and  continues  to refine its  operations  in Europe to fit the
European mold. On March 8, 1999, the Company  acquired the Nu Skin operations in
the United States,  and plans to acquire Big Planet and the other North American
Affiliates  in the second  quarter  of 1999.  Substantially  all of the  Company
personal care and nutritional  supplements are distributed in the United States.
The  Company  is  assuming  control  over the  United  States  operations  at an
important time. The newly combined  Pharmanex/IDN division was recently launched
in the United  States and Big Planet  continues  to develop  and  implement  its
technology and telecommunication products and services in the United States.

         Following are the weighted average  currency  exchange rates of $1 into
local currency for each of the Company's  markets in which revenue exceeded $5.0
million for at least one of the quarters listed:

                                      -21-



                           1996                                  1997                                  1998
            ----------------------------------    ----------------------------------    ----------------------------------
              1st      2nd      3rd      4th        1st      2nd      3rd      4th        1st      2nd      3rd      4th
            Quarter  Quarter  Quarter  Quarter    Quarter  Quarter  Quarter  Quarter    Quarter  Quarter  Quarter  Quarter
            -------  -------  -------  -------    -------  -------  -------  -------    -------  -------  -------  -------
                                                                                 
Japan(1)      105.8    107.5    109.0    112.9      121.4    119.1    118.1    125.6      128.2    135.9    139.5    119.3
Taiwan         27.4     27.4     27.5     27.5       27.5     27.7     28.4     31.0       32.8     33.6     34.5     32.6
Hong Kong       7.7      7.7      7.7      7.7        7.7      7.7      7.7      7.7        7.7      7.8      7.8      7.8
South Korea   782.6    786.5    815.5    829.4      863.9    889.6    894.8  1,097.0    1,585.7  1,392.6  1,327.0  1,278.9
Thailand       25.2     25.3     25.3     25.5       26.0     25.4     31.5     40.3       45.1     40.3     40.9     37.1

------------------

(1)     Since  January 1, 1992,  the highest and lowest  exchange  rates for the
        Japanese yen have been 147.3 and 80.6, respectively.



Competition

         Personal Care and Nutritional  Products.  The markets for personal care
and  nutritional  products  are large and  intensely  competitive.  The  Company
competes  directly with companies that  manufacture and market personal care and
nutritional  products in each of the Company's  product  categories  and product
lines.  The Company  competes  with other  companies  in the  personal  care and
nutritional  products industry by emphasizing the uniqueness,  value and premium
quality  of  the  Company's  products  and  the  convenience  of  the  Company's
distribution  system.  Many of the Company's  competitors have much greater name
recognition and financial resources than the Company. In addition, personal care
and  nutritional  products  can be  purchased  in a wide  variety of channels of
distribution.   While  the  Company  believes  that  consumers   appreciate  the
convenience  of ordering  products from home through a sales person or through a
catalog,  the buying habits of many consumers  accustomed to purchasing products
through  traditional  retail  channels are  difficult to change.  The  Company's
product offerings in each product category are also relatively small compared to
the wide variety of products offered by many other personal care and nutritional
product  companies.  There can be no assurance  that the Company's  business and
results of operations will not be affected  materially by market  conditions and
competition in the future. See "Risk Factors -- Competition."

         Technology  Products  and  Services;  Telecommunications.  The Internet
services and on-line  commerce market is new,  rapidly  evolving,  and intensely
competitive. The Company expects competition to intensify further in this market
in the future.  Barriers to entry for  e-commerce  are relatively low as current
and new  competitors  can  launch  new Web sites at  relatively  low  cost.  Big
Planet's  e-commerce  services also compete with other channels of distribution,
including  catalogue sales and traditional retail sales. Big Planet currently or
potentially  competes  with  other  companies  for  its  Internet  services  and
products,  including:  established  on-line  services such as America Online and
Microsoft Network, local, regional, and national Internet service providers such
as  MindSpring  and national  telecommunication  companies;  and other  numerous
e-commerce  Web sites  such as  Amazon.com  and  Buy.com.  Many of Big  Planet's
competitors have much greater name recognition and financial  resources than Big
Planet or the Company. In addition, the Company understands that some e-commerce
vendors  have  elected to sell  products  for little or no gross  margins and to
generate  revenue  through  the sale of  advertising.  Big  Planet  would have a
difficult  time  competing   based  on  price  with  such  vendors  because  its
distribution  system results in a commission  payment based on such sales. There
can be no assurance  that Big Planet's  business and results of operations  will
not be affected  materially by the intense  competition in the Internet  market.
See "Risk Factors -- Competition."

         The telecommunications industry is highly competitive.  Many of the Big
Planet's  existing  and  potential  competitors  in  this  market  segment  have
financial,  personnel, marketing, and other resources significantly greater

                                      -22-

than  those  of  the  Company  or Big  Planet,  as  well  as  other  competitive
advantages.  Increased  consolidation  and  strategic  alliances in the industry
resulting  from the  Telecommunications  Act of 1996 (the "Telecom Act of 1996")
could give rise to significant  new  competitors  to Big Planet.  Competition is
primarily on the basis of pricing,  transmission  quality,  network reliability,
and customer service and support. Big Planet may be at a disadvantage because it
does not have its own facilities and must rely on its ability to acquire quality
and  reliable  services  from  third-party  vendors at a price that allows it to
resell such services at competitive  rates. The ability of Big Planet to compete
effectively in this market will depend upon its ability to maintain high quality
services at prices equal to or below those charged by its competitors. There can
be no  assurance  that Big Planet or the Company  will be able to contract  with
third  parties to obtain rates that allow it to compete on the basis of price in
the future or that it will be able to successfully  compete in this market.  See
"Risk Factors - Competition."

         Network  Marketing  Companies.  The Company  also  competes  with other
direct selling organizations,  some of which have a longer operating history and
higher  visibility,  name  recognition,  and  financial  resources.  The leading
network marketing company in the Company's existing markets is Amway Corporation
and its affiliates. The Company competes for new distributors on the strength of
its multiple  business  opportunities,  product  offerings,  compensation  plan,
management  strength,  and appeal of its  international  operations.  Management
envisions  the  entry  of  many  more  direct  selling  organizations  into  the
marketplace as this channel of distribution expands over the next several years.
There can be no assurance that the Company will be able to successfully meet the
challenges posed by this increased competition. See "Risk Factors--Competition."

Intellectual Property

         The Company's major  trademarks are registered in the United States and
in many other countries,  and the Company considers its trademark  protection to
be very  important to its  business.  The major  trademarks  used by the Company
include the following:  Nu Skin, IDN,  Pharmanex,  LIFEPAK,  and Big Planet. The
Company  generally  registers its important  trademarks in the United States and
each market where the Company operates or has plans to operate.  In addition,  a
number  of  the  Company's   products  utilize   proprietary   technologies  and
formulations.

Government Regulation

         Direct Selling  Activities.  Direct selling activities are regulated by
various federal, state, and local governmental agencies in the United States and
foreign countries.  These laws and regulations are generally intended to prevent
fraudulent or deceptive schemes,  often referred to as "pyramid," "money games,"
"business  opportunity" or "chain sales" schemes, that promise quick rewards for
little or no effort,  require high entry  costs,  use high  pressure  recruiting
methods,  and/or do not involve legitimate products. The laws and regulations in
the  Company's  current  markets often (i) impose  certain  cancellation/product
return,   inventory   buy-backs  and   cooling-off   rights  for  consumers  and
distributors,  (ii) require the Company or its distributors to register with the
governmental agency, (iii) impose certain reporting requirements on the Company,
and/or (iv) impose various requirements,  such as requiring distributors to have
certain levels of retail sales to qualify to receive commissions, to ensure that
distributors are being compensated for sales of products and not for recruitment
of new distributors. The extent and provisions of these laws, however, vary from
country to country and can impose  significant  restrictions  and limitations on
the Company's  business  operations.  For example,  in South Korea,  the Company
cannot pay more than 35% of its revenues to its distributors in any given month.
In Germany,  the German Commercial Code prohibits the use of direct salespersons
to promote a  multi-level  marketing  arrangement  by making the  inducement  to
purchase  products for resale  illegal.  Accordingly,  the Company,  through its
German subsidiary,  sells its products to consumers through a "commercial agent"
rather  than a  wholesale  distributor.  A  commercial  agent is  similar  to an
employee.  Therefore,  Nu Skin is subject to potential tax and social  insurance
liability as well as agency law governing the termination of a commercial agent.

         Based on research  conducted in opening its existing markets (including
assistance  from  local  counsel),  the  nature  and  scope  of  inquiries  from
government  regulatory  authorities,  and the Company's history of operations in

                                      -23-

such markets to date, the Company believes that its method of distribution is in
compliance in all material  respects with the laws and  regulations  relating to
direct  selling  activities  of the  countries  in which the  Company  currently
operates. Certain countries,  including Singapore and China, currently have laws
in place that would prohibit or significantly  limit the Company from conducting
business in such markets in accordance with its existing  business model.  There
can be no assurance that the Company will be allowed to conduct  business in new
markets or continue to conduct  business in each of its  existing  markets.  See
"Risk Factors - Government Regulation of Direct Selling Activities."

         Regulation of Personal Care and Nutritional Supplements.  The Company's
personal care and nutrition  products and related  marketing and advertising are
subject to extensive  governmental  regulation by numerous  domestic and foreign
governmental  agencies and  authorities,  including  the FDA, the Federal  Trade
Commission (the "FTC"), the Consumer Product Safety  Commission,  and the United
States  Department  of  Agriculture  in the United  States,  and the Ministry of
Health and Welfare in Japan (the "MOHW").

         The  Company's  markets  have  varied  regulations  concerning  product
formulation,  labeling,  packaging, and importation.  These laws and regulations
often require the Company to, among other things: (i) reformulate products for a
specific market to meet the specific  product  formulation laws of such country;
(ii) conform  product  labeling to the  regulations  in each country;  and (iii)
register or qualify products with the applicable  government authority or obtain
necessary  approvals or file necessary  notifications  for the marketing of such
products. For example, in Japan, the MOHW requires the Company to have an import
business license and to register each personal care product imported into Japan.
The  Company  has  also  had  to  reformulate  many  products  to  satisfy  MOHW
regulations.  In Taiwan, all "medicated"  cosmetic and  pharmaceutical  products
require registration.  These regulations can limit the ability of the Company to
import  certain  products  into  certain  of  its  markets  and  can  delay  the
introduction   of  products  into  markets  as  the  Company  goes  through  the
registration  and  approval  process  for such  products.  The sale of  cosmetic
products is regulated in the European  Union ("EU")  member  states under the EU
Cosmetics Directive,  which requires a uniform application for foreign companies
making personal care product sales.

         Nutritional   supplements  are  strictly  regulated  in  the  Company's
markets.  The  Company's  markets  have  varied  regulations  that  apply to and
distinguish   dietary  health   supplements  from  "drugs"  or   "pharmaceutical
products." For example,  the Company's  products are regulated by the FDA in the
United  States under the Federal Food,  Drug and Cosmetic Act (the "FDCA").  The
FDCA has been amended  several  times with respect to  nutritional  supplements,
most  recently  by the  Nutrition  Labeling  and  Education  Act and the Dietary
Supplement  Health and  Education Act  ("DSHEA").  DSHEA  establishes  rules for
determining  whether  a  product  is  a  nutritional  supplement.  Under  DSHEA,
nutritional  supplements  are  regulated  more like  foods than  drugs,  are not
subject  to the food  additive  provisions  of the law,  and are  generally  not
required  to  undergo  regulatory  clearance  prior  to  market.  None  of  this
infringes,  however, upon the FDA's power to remove an unsafe substance from the
market,  but the law  clearly  shifts the burden of proof to the FDA.  In Japan,
regulations  strictly limit the types of claims and regulations that can be made
regarding the efficacy of nutritional supplements. In the event a product, or an
ingredient in a product,  is classified as a drug or  pharmaceutical  product in
any market, the Company will generally not be able to distribute such product in
such market through its distribution  channel because of the strict restrictions
applicable to drug and pharmaceutical products.

         Many of the Company's existing markets also regulate product claims and
advertising.  These laws regulate the types of claims and  representations  that
can  be  made   regarding  the  efficacy  of  products,   particularly   dietary
supplements. For example, in the United States the Company is unable to make any
claim that any of its nutritional  supplements  will diagnose,  cure,  mitigate,
treat, or prevent disease. DSHEA, however, permits substantiated,  truthful, and
non-misleading statements of nutritional support to be made in labeling, such as
statements describing general well-being resulting from consumption of a dietary
ingredient  or the role of a

                                      -24-

nutrient or dietary  ingredient  in  affecting or  maintaining  a structure or a
function of the body. The FDA recently issued a proposed rule  concerning  these
issues. The FTC similarly requires that any claims be substantiated.  One of the
strategic  purposes of the  acquisition  of Pharmanex was to provide the Company
with  additional  resources to enhance the ability of the Company to comply with
these  requirements.  In Japan,  the Company and its  distributors  are severely
restricted in making any claims  concerning the health benefits of the Company's
nutritional supplements. Accordingly, these regulations can limit the ability of
the Company and its distributors to inform consumers of the full benefits of the
Company's products.  See "Risk Factors -- Government  Regulation of Products and
Marketing; Import Restrictions."

         The Company and its  vendors are also  subject to laws and  regulations
governing the manufacturing of its products.  For example,  in the United States
the FDA regulations establish Good Manufacturing  Practices for foods and drugs.
Detailed  Good  Manufacturing  Practices  have  been  proposed  by the  FDA  for
nutritional   supplements;   however,  no  regulations  establishing  such  Good
Manufacturing Practices have been adopted.

         To date, the Company has not experienced any difficulty maintaining its
import licenses but has experienced  complications  regarding  health and safety
and food and drug  regulations for nutritional  products.  Many of the Company's
products  have  required  reformulation  to comply with local  requirements.  In
addition,  in Europe there is no uniform  legislation  governing the manufacture
and  sale  of   nutritional   products.   Complex   legislation   governing  the
manufacturing and sale of nutritional products in this market have inhibited the
ability of the Company to gain quick  access to this market for its  nutritional
supplements  and could  continue  to  adversely  affect  and delay  sales of the
Company's nutritional supplements in these markets,  particularly Germany, which
already  has  a  large  nutritional,  herbal,  and  dietary  products  industry.
Currently,  the Company is only actively marketing a few of its core nutritional
products in a limited number of countries in its European market.

         Telecommunications Regulation. Following the acquisition of Big Planet,
the  Company,  through  Big  Planet,  will be  subject  to  varying  degrees  of
telecommunications regulation in each of the jurisdictions in which it operates.
As a  nondominant  carrier in the United  States,  the  Company's  provision  of
international  and  domestic  long  distance   telecommunications   services  is
generally  regulated  on a  streamlined  basis.  Despite  recent  trends  toward
deregulation,  some  countries  do  not  currently  permit  competition  in  the
provision of public switched voice telecommunications services.

         United    States    Regulation    of   Domestic    and    International
Telecommunications Services

         In  the   United   States,   Big   Planet's   provision   of   domestic
telecommunications  service is subject to the  provisions of the  Communications
Act,  as amended by the  Telecom  Act of 1996,  and the  Federal  Communications
Commission ("FCC") regulations promulgated thereunder, as well as the applicable
laws and regulations of the various states. The FCC exercises  jurisdiction over
all facilities of, and services offered by,  telecommunications  common carriers
to the extent  those  facilities  are used to provide,  originate,  or terminate
interstate or international communications.  State regulatory commissions retain
some  jurisdiction  over the same facilities and services to the extent they are
used to originate or terminate intrastate common carrier communications. The FCC
and  relevant  state   authorities   regulate  the  ownership  of   transmission
facilities,  the provision of services, and the terms and conditions under which
such services are provided. Nondominant carriers such as Big Planet are required
by federal  and state law and  regulations  to file  tariffs  listing the rates,
terms, and conditions for the services they provide. In addition,  Big Planet is
subject to contribution  requirements  for federal and state  universal  service
funds, which serve to fund affordable telephone service in designated sectors.

         With regard to regulation of international  telecommunications services
in the United  States,  common  carriers,  such as Big Planet,  are  required to
obtain authority under Section 214 of the  Communications Act and are subject to
a  variety  of   international   service   regulations,   including   the  FCC's
International Settlements Policy,

                                      -25-

which governs permissible  arrangements between United States carriers and their
foreign correspondents to settle the cost of terminating traffic on each other's
networks and settlement  rates,  and rules requiring the filing of international
tariffs,  carrier contracts (including foreign carrier agreements),  and traffic
and revenue reports.

         Regulation of Telecommunications Services in Foreign Countries

         Many  overseas   telecommunications  markets  are  undergoing  dramatic
changes as a result of privatization and deregulation. In Europe, the regulation
of the  telecommunications  industry is governed at a supranational level by EU,
which  has  developed  a  regulatory   framework  aimed  at  ensuring  an  open,
competitive  telecommunications  market.  Each EU member  state has a  different
regulatory  regime,  and the  requirements  for Big  Planet to obtain  necessary
licenses  vary  considerably  from one member state to another and are likely to
change as  competition  is permitted in new service  sectors.  In other overseas
markets,  Big Planet would be subject to the  regulatory  regimes in each of the
countries in which it seeks to conduct  business.  Local  regulations range from
permissive to  restrictive,  depending  upon the country.  Despite recent trends
toward  deregulation,  some countries do not currently permit competition in the
provision of public switched voice telecommunications services, which will limit
the  ability of Big Planet to provide  telecommunication  services in all of the
Company's markets.

         Internet Access

         In  the  United  States,   Internet  service  providers  are  generally
considered  "enhanced  service  providers" and are exempt from federal and state
regulations  governing common carriers.  Accordingly,  Big Planet's provision of
Internet access  services is currently  exempt from tariff,  certification,  and
rate regulation. Nevertheless,  regulations governing disclosure of confidential
information, copyright, excise tax, and other requirements that may apply to Big
Planet's  provision of Internet  access services could be adopted in the future.
In addition,  the  applicability of existing laws governing many of these issues
to the Internet is  uncertain.  The majority of such laws were adopted  prior to
the advent of the Internet and related  technologies  and do not address  unique
issues  associated with the Internet and related  technologies.  There can be no
assurance  that the Company's  operation  will not be adversely  affected by the
adoption of any such laws or the  application  of existing laws to the Internet.
In addition,  there can be no assurance that regulatory  requirements in markets
outside of the  United  States  will not  adversely  affect  the  ability of the
Company to implement Internet services in such markets.

         Other Regulatory  Issues.  As a United States entity operating  through
subsidiaries  in  foreign  jurisdictions,  the  Company  is  subject  to foreign
exchange  control and  transfer  pricing  laws that  regulate  the flow of funds
between its  subsidiaries  and the Company  for  product  purchases,  management
services,  and  contractual  obligations  such  as the  payment  of  distributor
commissions.  The  Company  believes  that it operates  in  compliance  with all
applicable  foreign exchange control and transfer pricing laws.  However,  there
can be no assurance  that the Company will  continue to be found to be operating
in compliance with foreign  exchange  control and transfer pricing laws, or that
such laws will not be modified,  which, as a result,  may require changes in the
Company's operating procedures.

         As is the case with  most  companies  which  operate  in the  Company's
product  segment,  the Company  has from time to time  received  inquiries  from
various government  regulatory  authorities regarding the nature of its business
and  other  issues  such as  compliance  with  local  direct  selling,  customs,
taxation, foreign exchange control, securities, and other laws. Although to date
none of these  inquiries  has  resulted in a finding  materially  adverse to the
Company,   adverse  publicity   resulting  from  inquiries  into  the  Company's
operations by certain government  agencies in the early 1990s,  stemming in part
out of  inappropriate  product and earnings claims by  distributors,  materially
adversely affected the Company's  business and results of operations.  There can
be no assurance that the Company will not face similar  inquiries in the future,
which,  either as a result of findings

                                      -26-

adverse to the Company or as a result of adverse  publicity  resulting  from the
instigation  of such  inquiries,  could  have a material  adverse  effect on the
Company's  business  and results of  operations.  See "Risk  Factors -- Risks of
Government Inquiry and Investigation."

         Based on the Company's  experience and research  (including  assistance
from counsel) and the nature and scope of inquiries from  government  regulatory
authorities,  the Company  believes that it is in material  compliance  with all
regulations  applicable to it.  Despite this belief,  the Company could be found
not to be in material compliance with existing regulations as a result of, among
other things, the considerable  interpretative and enforcement  discretion given
to regulators or misconduct by independent distributors.  In 1994, NSI and three
of its  distributors  entered into a consent decree with the FTC with respect to
its investigation of certain product claims and distributor practices,  pursuant
to which NSI paid approximately $1.0 million to settle the FTC investigation. In
August  1997,  NSI  reached a  settlement  with the FTC with  respect to certain
product  claims and its  compliance  with the 1994 consent  decree,  pursuant to
which settlement NSI paid $1.5 million to the FTC.

          Any assertion or  determination  that the Company or its  distributors
are not in compliance  with existing laws or  regulations  could have a material
adverse effect on the Company's business and results of operations. In addition,
in any  country or  jurisdiction,  the  adoption of new laws or  regulations  or
changes in the  interpretation  of existing laws or  regulations  could generate
negative  publicity  and/or  have a  material  adverse  effect on the  Company's
business and results of operations.  The Company cannot determine the effect, if
any, that future governmental  regulations or administrative  orders may have on
the  Company's  business  and  results  of  operations.  Moreover,  governmental
regulations  in  countries  where  the  Company  plans  to  commence  or  expand
operations  may prevent,  delay,  or limit  market entry of certain  products or
require the reformulation of such products. Regulatory action, whether or not it
results in a final  determination  adverse to the Company,  has the potential to
create  negative  publicity,  with  detrimental  effects on the  motivation  and
recruitment  of  distributors  and,  consequently,  on the  Company's  sales and
earnings. See "Risk Factors -- Risks of Government Inquiry and Investigation."

Employees

         As of December 31, 1998, the Company had approximately  1,500 full-time
and  part-time  employees.  None of the employees is  represented  by a union or
other collective  bargaining  group. The Company believes its relationship  with
its employees is good,  and does not  currently  foresee a shortage in qualified
personnel needed to operate the business.

Risk Factors

         There are certain  significant risks facing the Company,  many of which
are  substantial  in  nature.  The  following  risks and  information  should be
considered in connection with the other information contained in this filing.

         Economic and Political  Conditions in the  Company's  Markets.  Through
1997 and 1998,  economic and  political  conditions  in certain of the Company's
markets have  deteriorated.  These adverse  conditions  have been reflected most
significantly in the Company's operating results in its North Asia and Southeast
Asia market  regions.  Many countries  currently labor under declining stock and
currency markets,  mounting bad bank debt, bankruptcies involving large business
enterprises,  excess capacity, declining demand for foreign goods, and political
unrest.  Many commentators  expect economic and political  conditions in certain
markets to worsen in the  foreseeable  future.  Adverse  economic  or  political
conditions in Japan, which accounted for approximately 70% of the Company's 1998
revenues,  could  have a  particularly  adverse  impact on the  Company  and its
results of operations.

                                      -27-

         Currency  Fluctuation and Exchange Rate Factors.  Most of the Company's
revenue are recognized  primarily  outside of the United States while  inventory
purchases are primarily  transacted in United States dollars from vendors in the
United  States.  Each  entity's  local  currency is  considered  the  functional
currency.  All revenue and expenses are translated at weighted  average exchange
rates for the periods reported.  Therefore,  the Company's  reported revenue and
net income  will be  positively  impacted by a  weakening  of the United  States
dollar and will be negatively  impacted by a strengthening  of the United States
dollar.  The  weakening of the Japanese Yen relative to the United States dollar
significantly  affects  the  Company's  reported  revenue  and net income  since
approximately  70% of the  Company's  revenue  is  currently  derived  from  the
Japanese  market.  Given the  uncertainty  of exchange  rate  fluctuations,  the
Company cannot estimate the effect of these fluctuations on its future business,
product pricing, results of operations, or financial condition. However, because
nearly all of the  Company's  revenue is  realized in local  currencies  and the
majority  of its cost of sales is  denominated  in United  States  dollars,  the
Company's gross profits will be positively affected by a weakening in the United
States dollar and will be negatively  affected by a strengthening  in the United
States  dollar.  The Company  reduces its  exposure to  fluctuations  in foreign
exchange  rates by  creating  offsetting  positions  through  the use of foreign
currency exchange contracts. The Company does not use such financial instruments
for trading or speculative purposes.  The Company regularly monitors its foreign
currency risks and  periodically  takes measures to reduce the impact of foreign
exchange   fluctuations  on  the  Company's  operating  results.  See  "Regional
Profiles."

         Reliance upon  Independent  Distributors.  The Company  distributes its
products  exclusively  through  independent  distributors  who  have  contracted
directly with the Company,  through its subsidiary NSI.  Distributor  agreements
are voluntarily terminable by distributors at any time. The Company's revenue is
directly dependent upon the efforts of these independent  distributors,  and any
growth in future sales volume will  require an increase in the  productivity  of
these distributors and/or the growth in the total number of distributors.  As is
typical in the direct selling  industry,  there is turnover in distributors from
year to year,  which requires the sponsoring and training of new distributors by
existing  distributors to maintain or increase the overall distributor force and
motivate  new  and  existing  distributors.  The  Company  experiences  seasonal
decreases in  distributor  sponsoring and product sales in some of the countries
in which the Company operates  because of local holidays and customary  vacation
periods. The size of the distribution force can also be particularly impacted by
general economic and business conditions and a number of intangible factors such
as adverse publicity  regarding the Company,  or the public's  perception of the
Company's  products,   product  ingredients,   distributors  or  direct  selling
businesses  in  general.  Historically,  the Company  has  experienced  periodic
fluctuations in the level of distributor sponsorship (as measured by distributor
applications).  However,  because  of the  number of  factors  that  impact  the
sponsoring of new distributors, and the fact that the Company has little control
over the level of  sponsorship of new  distributors,  the Company cannot predict
the timing or degree of those  fluctuations.  There can be no assurance that the
number or  productivity  of the  Company's  distributors  will be  sustained  at
current  levels  or  increased  in  the  future.  In  addition,  the  number  of
distributors  as a percentage  of the  population  in a given  country or market
could  theoretically  reach  levels that become  difficult  to exceed due to the
finite  number  of  persons   inclined  to  pursue  a  direct  selling  business
opportunity.

         Because distributors are independent contractors, the Company is not in
a position to provide the same level of direction,  motivation, and oversight as
it  would  with  respect  to its  own  employees.  Although  the  Company  has a
compliance  department  responsible  for the  enforcement  of the  policies  and
procedures that govern distributor conduct, it can be difficult to enforce these
policies and procedures  because of the large number of  distributors  and their
independent  status,  as well as the impact of regulations in certain  countries
that limit the ability of the Company to monitor and control the sales practices
of distributors or terminate distributors. See "Distribution System."

         Risks   Related  to  the   Integration   of  Recent  and   Contemplated
Acquisitions.  The  Company  believes  that  its  recent  acquisitions  of  NSI,
Pharmanex,  and the business  operations of Nu Skin USA,  Inc., and its proposed

                                      -28-

acquisitions of the remaining private North American  Affiliates and Big Planet,
have created or will create  opportunities  for  long-term  efficiencies  in the
Company's  operations  and other benefits that should  positively  affect future
results of the combined operations of the Company. However, no assurances can be
given  whether or when such  efficiencies  and  benefits  will be  realized.  In
addition, the Company has become more complex and diverse since the acquisitions
of NSI,  Pharmanex,  and the business  operations of Nu Skin USA, Inc., and will
become even more so after the  consummation of the acquisition of Big Planet and
the  remaining  private  North  American  Affiliates.  The  combination  of  the
Company's  business with that of its recent and contemplated  acquisitions  will
present  difficult  challenges  for  the  Company's  management  because  of the
increased time and resources required to manage a complex  world-wide  business.
Also, the accounting for the completed and contemplated  acquisitions  using the
purchase method has resulted and could result in significant  intangible  assets
or a significant  charge  against  operations,  or both,  which could  adversely
affect future results of operations. While management and the Board of Directors
of the Company believe that the continued integration of the recent acquisitions
and the  contemplated  acquisition  of Big Planet  will be  effected in a manner
which will  increase  the value of the Company,  no assurance  can be given that
such  realization  of value  will be  achieved.  The  Company  will also need to
integrate the products of Pharmanex,  which until recently were marketed only in
the mass market, into the Company's direct sales distribution  system. There can
be no assurance  that the Company  will be able to  successfully  integrate  the
products of Pharmanex  into the  Company's  current  distribution  system,  that
Pharmanex  products will gain  acceptance  in this channel,  or that the Company
will  not  incur   significant  costs  and  expenses  in  connection  with  such
integration.  The closing of the proposed Big Planet  acquisition  is subject to
certain  contingencies  including  the  satisfactory  completion  of  definitive
documentation  and the Company's due diligence  investigation  of Big Planet and
the receipt of various  governmental  approvals.  The Company cannot assure that
the Big Planet acquisition will be consummated.  In addition,  Big Planet,  like
many Internet companies,  has experienced  significant operating losses to date.
There can be no assurance that Big Planet will be able to operate  profitably in
the highly competitive  Internet market in the near future or that such products
can be  profitably  marketed  through a network  marketing  system.  See "Recent
Developments."

         Government  Regulation of Direct  Selling  Activities.  Direct  selling
activities are regulated by various  governmental  agencies in the United States
and foreign  countries.  Direct  selling in certain of the Company's  markets is
restricted or subject to stringent  regulation.  There can be no assurances that
regulatory  authorities  in the Company's  existing  markets will not impose new
legislation or change existing  legislation that adversely affects the Company's
business in those markets,  or that new judicial  interpretation of existing law
may be issued that  adversely  affect the  Company's  business.  There can be no
assurance  that the Company  will be allowed to conduct  business in each of its
existing markets or potential new markets. See "Government  Regulation -- Direct
Selling Activities."

         Government  Regulation of Products and Marketing;  Import Restrictions.
The Company is subject to or affected by extensive governmental  regulations not
specifically related to network marketing.  Such regulations govern, among other
things:

       *      The Company's personal care products and nutritional supplements;

       *      The  Company's  telecommunication  products and  services  offered
              through Big Planet;

       *      Product  formulation,   manufacturing,  labeling,  packaging,  and
              importation;

       *      Product claims and advertising, whether made by the Company or its
              distributors;

       *      Fair trade and distributor practices;

                                      -29-

       *      Taxes,  transfer  pricing,  and  similar  regulations  that affect
              foreign taxable income and customs duties; and

       *      foreign companies generally.

         With the exception of a small  percentage of revenue,  virtually all of
the  Company's  sales  historically  have been  derived from the sale of its own
products.  All of  those  products  historically  have  been  imported  into the
countries in which they were ultimately sold. The countries in which the Company
currently conducts business impose various legal restrictions on imports. In any
given country,  duties on imports may be changed to materially  adversely affect
the Company's sales and competitive position compared to locally produced goods.
In some  jurisdictions,  regulators  have or may prevent the  importation of the
Company's products altogether.

         The  Company's  personal  care and  nutritional  products  and  related
marketing and advertising also are subject to extensive governmental regulation.
The Company may not be able to  introduce  its  nutritional  products in markets
outside the United States if it is unable to obtain regulatory  approval of such
products or if such products or any  ingredients  contained in such products are
prohibited  in such  markets.  The  Company may also be  prohibited  from making
therapeutic  claims  regarding  such  products  in certain  markets  even if the
Company may have  research  and  independent  studies  supporting  such  claims.
Present or future  health and safety or food and drug  regulations,  or judicial
interpretations thereof, could delay or prevent the introduction of new products
into a given country or  marketplace or suspend or prohibit the sale of existing
products  in  such  country  or  marketplace.   See  "Government  Regulation  --
Regulation of Personal Care and Nutritional Supplements."

         The Company's  proposed  provision of Internet access services  through
Big Planet is currently exempt from significant regulation in the United States.
However,  the  applicability  of  existing  laws  to the  Internet  and  related
technologies is uncertain, and laws and regulations may be adopted that apply to
such  technologies  in the future.  There can be no assurance that the Company's
operations  will not be  adversely  effected by the adoption of any such laws or
the application of existing laws to the Internet. In addition, the Company could
be subject to  regulations  in its foreign  markets that are  applicable  to the
Internet.  There can be no  assurance  that any of such laws  could not delay or
prevent the Company from  introducing Big Planet products and services into such
markets,  or otherwise  adversely  affect the ability of the Company  operate in
these markets. See "Government Regulation -- Telecommunications Regulation."

         As a United States entity  operating  through  subsidiaries  in foreign
jurisdictions,  the Company is subject to foreign  exchange control and transfer
pricing  laws  that  regulate  the  flow  of  funds  between  the  Company,  its
subsidiaries,  and  affiliates.  There can be no assurance that the Company will
continue to operate in compliance with foreign customs,  exchange  control,  and
transfer  pricing  laws,  or that such laws will not be  modified,  which,  as a
result,  may  require  changes  in  the  Company's  operating  procedures.   See
"Government Regulation -- Other Regulatory Issues."

         Risks of Government Inquiry and Investigation. As is the case with most
direct sales companies,  the Company has from time to time,  received  inquiries
from  various  government  regulatory  authorities  regarding  the nature of its
business and other issues such as compliance with local business opportunity and
securities laws. Also, its subsidiaries are periodically  subject to reviews and
audits by various governmental agencies.  There is no assurance that the Company
or its subsidiaries will not face similar inquiries and other  investigations in
the future.  Any  assertion or  determination  that the  Company,  or any of its
distributors,  are not in compliance  with existing laws or  regulations,  could
potentially have a material adverse effect on the Company's business and results
of operations. In addition, in any country or jurisdiction,  the adoption of new
laws or  regulations  or  changes  in the  interpretation  of  existing  laws or
regulations  could generate  negative  publicity  and/or have a material adverse
effect on its business and results of operations.  The Company cannot  determine
the effect, if any, that future

                                      -30-

governmental  regulations or administrative  orders may have on its business and
results of operations. Moreover, governmental regulations in countries where the
Company  plans to commence or expand  operations  may prevent,  delay,  or limit
market entry of certain products or require the  reformulation of such products.
Regulatory action, whether or not it results in a final determination adverse to
the Company,  has the potential to create negative  publicity,  with detrimental
effects on the motivation and recruitment of distributors and, consequently,  on
the  Company's  revenue  and net income.  See  "Government  Regulation  -- Other
Regulatory Issues."

         Reliance on Limited Suppliers.  The Company currently acquires products
and  ingredients  from sole  suppliers or from  suppliers  considered  to be the
superior suppliers of such ingredients. The loss of any of these suppliers could
have a  material  adverse  effect  on the  Company's  business  and  results  of
operations. Because certain of the Company's botanical products are derived from
crops that can only be harvested once a year, problems with a certain crop could
limit the ability of the Company to produce a product associated with that plant
species in a given year. See "Sourcing and Production."

         Competition.   The  markets  for  the   Company's   personal  care  and
nutritional  products,  and the technology  products and services offered by Big
Planet are  intensely  competitive.  The Company also competes with other direct
selling organizations.  Many of the Company's competitors have much greater name
recognition  and  financial  resources  than the Company,  which may give them a
competitive advantage. There can be no assurance that the Company's business and
results of operations will not be affected  materially by market  conditions and
competition in the future.  Although the Company distributes certain products it
considers proprietary,  it does not currently have significant patent protection
for its products. In addition, competitors may also introduce products utilizing
the same  natural  ingredients  and herbs as the  Company's  proprietary  health
supplement CHOLESTIN, the Company believes competitors have introduced competing
products  utilizing red yeast rice.  Because of  restrictions  under  regulatory
requirements  concerning  claims  that  can be  made  with  respect  to  dietary
supplements, the Company may have a difficlult time differentiating its products
from those of competitors. See "Competition."

         Year 2000 Risks. The Company may not accurately  identify all potential
Year 2000 problems within its business,  and the corrective measures that it may
implement may be ineffective  or incomplete.  The Company cannot assure that Big
Planet  will not  experience  Year 2000  problems  related to or  affecting  its
business. Any such problems could adversely affect the Company. The Company also
contracts  with many  third  parties  that  could be  affected  by the Year 2000
problem,  such as technology and  telecommunication  service providers and other
suppliers and manufacturers. If any of these or other third parties on which the
Company relies  experience Year 2000 problems,  the Company's  business could be
adversely  affected.  See  "Management's  Discussion  and  Analysis of Financial
Condition  and  Results  of  Operations"  in  the  Company's  Annual  Report  to
Stockholders, sections of which are attached hereto as Exhibit 13.

         Risks  Related to  Potential  Changes in  Business  Model.  The Company
believes  that  direct  sellers  will  need to adapt  their  business  models to
integrate the Internet into their operations as more and more consumers purchase
goods and services over the Internet instead of through  traditional  retail and
direct sales  channels.  The Company  cannot assure that it or its  distributors
will be able to adequately  adapt to the use of new technology or sales channels
or  effectively  integrate the Internet into their  respective  operations.  See
"Distribution System."

         Potential  Effects  of  Adverse  Publicity.  The size of the  Company's
distribution  force  and  the  results  of  the  Company's   operations  can  be
particularly  impacted by adverse  publicity  regarding  the  Company,  or their
competitors,  including  publicity  regarding the legality of network marketing,
the quality of the Company's  products and product  ingredients  or those of its
competitors,   regulatory   investigations  of  the  Company  or  the  Company's
competitors and their products, distributor actions, and the public's perception
of the Company's  distributors  and direct  selling  businesses  generally.  The
Company's  operations in the past have been  adversely  affected by such adverse
publicity in certain  markets,  and there can be no assurance that the Company's
operations  will not be  adversely

                                      -31-

affected  in the  future  by  adverse  publicity  concerning  the  Company,  its
distribution system, or network marketing in general.

         Control by Existing Stockholders;  Anti-Takeover Effect of Dual Classes
of  Common  Stock.  The  shares of Class B Common  Stock,  which are held by the
original  stockholders  of NSI and their  affiliates,  enjoy  ten to one  voting
privileges over the shares of Class A Common Stock until the outstanding  shares
of Class B Common Stock constitute less than 10% of the total outstanding shares
of Common Stock. These stockholders and certain of their affiliates collectively
own 100% of the  outstanding  shares of the Class B Common  Stock,  representing
more than 90% of the combined voting power of the  outstanding  shares of Common
Stock. Accordingly,  these stockholders and certain of their affiliates,  acting
fully or partially in concert,  will have the ability to control the election of
the  Board  of  Directors  of the  Company  and thus the  direction  and  future
operations of the Company without the supporting  vote of any other  stockholder
of the Company,  including decisions  regarding  acquisitions and other business
opportunities,  the  declaration  of  dividends,  and the issuance of additional
shares  of  Class A  Common  Stock  and  other  securities.  As  long  as  these
stockholders  are majority  stockholders of the Company,  assuming they elect to
act in concert,  third parties will not be able to obtain control of the Company
through purchases of shares of Class A Common Stock.

         Taxation Risks and Transfer Pricing. The Company is subject to taxation
in the United States, where it is incorporated, at a statutory corporate federal
tax rate of 35.0% plus any  applicable  state income  taxes.  In addition,  each
subsidiary is subject to taxation in the country in which it operates,  at rates
above and below the  current tax rate in the United  States.  For  example,  the
Company's  subsidiary  in Japan has  historically  been subject to a tax rate of
approximately 57%. The Company is eligible to receive foreign tax credits in the
U.S. for the amount of foreign taxes  actually  paid in a given  period.  In the
event that the Company's operations in high tax jurisdictions such as Japan grow
disproportionately to the rest of the Company's operations,  the Company will be
unable to fully  utilize  its  foreign  tax  credits in the U.S.,  which  could,
accordingly, result in the Company paying a higher overall effective tax rate on
its worldwide operations.

         Because the  subsidiaries  operate  outside of the United  States,  the
Company is subject to the jurisdiction of numerous  foreign tax authorities.  In
addition to closely monitoring the subsidiaries' locally based income, these tax
authorities  regulate and restrict  various  corporate  transactions,  including
intercompany  transfers.  The Company believes that the tax authorities in Japan
and South Korea are  particularly  active in  challenging  the tax structures of
foreign  corporations  and their  intercompany  transfers.  Although the Company
believes that its tax and transfer  pricing  structures are in compliance in all
material respects with the laws of every  jurisdiction in which it operates,  no
assurance can be given that these  structures  will not be challenged by foreign
tax  authorities  or  that  such  challenges  or any  required  changes  in such
structures will not have a material adverse effect on the Company's  business or
results of operations.

         Product  Liability.  The Company may be subject,  under applicable laws
and  regulations,  to  liability  for loss or  injury  caused  by its  products.
Accordingly,  the Company  maintains a policy covering product  liability claims
for itself and its affiliates  with a $1 million per claim and $1 million annual
aggregate  limit and an  umbrella  policy  with a $40  million per claim and $40
million annual aggregate limit. Although the Company has not been the subject of
material product  liability  claims,  no assurance can be given that the Company
may not be exposed to future product liability  claims,  and, if any such claims
are  successful,  there can be no assurance  that the Company will be adequately
covered by insurance or have sufficient resources to pay such claims.

         Note Regarding Forward-Looking  Statements.  Certain statements made in
this filing under the caption "Business" are "forward-looking statements" within
the meaning of Section 21E of the  Securities  Exchange Act of 1934,  as amended
(the "Exchange Act"). In addition, when used in this Report the words or phrases
"will likely

                                      -32-

result," "expects,"  "intends," "will continue," "is anticipated,"  "estimates,"
"projects,"   "management   believes,"   "the  Company   believes"  and  similar
expressions  are intended to identify  "forward-looking  statements"  within the
meaning of the Exchange Act.

         Forward-looking  statements  include plans and objectives of management
for future operations,  including plans and objectives  relating to the products
and the future economic  performance of the Company in each country in which the
Company operates and the financial results of the Company. These forward-looking
statements involve risks and uncertainties and are based on certain  assumptions
that may not be realized. Actual results and outcomes may differ materially from
those discussed or anticipated.  The  forward-looking  statements and associated
risks set forth herein  relate to the: (i) proposed  acquisitions  of Big Planet
and the remaining  private North American  Affiliates,  (ii) proposed shift to a
strategic,    product-based   divisional   operating   structure   and   related
modifications of the Global  Compensation Plan; (iii) expansion of the Company's
market share in its current markets;  (iv) Company's  entrance into new markets;
(v)  development of new products and new product lines tailored to appeal to the
particular needs of consumers in specific  markets;  (vi) stimulation of product
sales by  introducing  new products and  reintroducing  existing  products  with
improvements;  (vii) creation of new nutritional  products  through the research
and development capabilities of Pharmanex; (viii) establishment of relationships
with  major  universities  to  assist in  nutritional  product  development  and
testing;  (ix) establishment of strategic  relationships to expand the Company's
and Big Planet's products offered for sale on the Internet;  (x) enhancement and
expansion of Big Planet's  telecommunication  and technology  services and other
products,  including  the offering of wireless  services  through a  third-party
wireless  service  provider and prepaid paging  products  through  SkyTel;  (xi)
promotion of distributor growth,  retention, and leadership through local market
initiatives; (xii) upgrading of the Company's technological resources to support
distributors,  including  using the Internet in  distributing  products;  (xiii)
utilization  of  technological  advancements  to improve  the  Company's  direct
selling  efforts;  and (xiv)  obtaining  of  regulatory  approvals  for  certain
products.

         All  forward-looking  statements are subject to known and unknown risks
and  uncertainties,  including  those  discussed  in the  above-referenced  Risk
Factors,  that could cause actual results to differ  materially  from historical
results and those  presently  anticipated  or projected.  The Company  wishes to
caution  readers  not  to  place  undue  reliance  on any  such  forward-looking
statements, which speak only as of the date made.

         The Company wishes to further advise readers that the important factors
presented  in the  above-referenced  Risk  Factors  could  affect the  Company's
financial  performance  and could cause the Company's  actual results for future
periods to differ materially from any views or statements expressed with respect
to future periods. Important factors and risks that might cause such differences
include, but are not limited to (a) adverse economic and political conditions in
some of the Company's markets,  particularly in the Company's Asian markets; (b)
fluctuations  in foreign  currency  values relative to the United States dollar,
(c) factors related to the Company's reliance upon independent distributors, (d)
risks  related  to the  continued  integration  of  recent  acquisitions  by the
Company;  (e) the  possibility  the proposed  acquisitions of Big Planet and the
remaining  private North  American  Affiliates may not be  consummated,  (f) the
inability of the Company to gain market  acceptance of new  products,  including
the  Pharmanex  products and Big Planet  products and services,  (g)  government
regulation of the Company's direct selling activities in its existing and future
markets,  (h)  government  regulation of products and marketing  generally,  (i)
risks  inherent in the  importation,  regulation,  and sale of personal care and
nutritional  products in the Company's  markets,  (j) other  regulatory  issues,
including  regulatory  action against the Company or its  distributors in any of
the Company's  markets,  (k) the Company's  reliance on limited suppliers of the
Company's  products,  (l)  competition  in the  Company's  existing  and  future
markets, (m) risks that the Company's and its vendors' plans to remedy Year 2000
issues may be  inadequate,  which could result in  disruptions  of the Company's
business,  and  (n)  risks  related  to  potential  changes  in  direct  selling
practices, particularly those changes prompted by changes in technology.

                                      -33-

         In light of the significant  uncertainties  inherent in forward-looking
statements,  the  inclusion  of any such  statement  should not be regarded as a
representation  by the Company or any other person that the  objectives or plans
of the Company will be achieved.  The Company disclaims any obligation or intent
to update  any such  factors or  forward-looking  statements  to reflect  future
events or developments.

                                      -34-

ITEM 2.PROPERTIES

         The Company  generally  leases its warehouse,  office,  or distribution
facilities  in each  geographic  region  in  which  the  Company  currently  has
operations.  Nu Skin believes that its existing  facilities are adequate for its
current  operations  in  each  of its  existing  markets.  The  following  table
summarizes,  as of  March  5,  1999,  the  Company's  major  leased  office  and
distribution facilities.

Location                 Function                        Approximate Square Feet
--------                 --------                        -----------------------
Provo, Utah              Distribution center                      198,000
Provo, Utah              Corporate offices                        125,000
Los Angeles, California  Warehouse                                126,000
Yokohama, Japan          Warehouse                                 37,000
Tokyo, Japan             Central office/distribution center        44,000
Taipei, Taiwan           Central office/distribution center        26,000
Nankan, Taiwan           Warehouse/distribution center             37,000
Venlo, Netherlands       Warehouse/offices                         20,000

In  connection  with the  acquisition  of  Pharmanex,  the  Company  acquired  a
production facility located in Huzhou, Zhejiang Province,  China. The design and
construction  of this  extraction  and  purification  facility was  completed in
October 1994 and on-line production began in November 1994.

ITEM 3.  LEGAL PROCEEDINGS

         NSI is a party to an  action  entitled  Natalie  Capone  on  behalf  of
Herself and All Others  Similarly  Situated  v. Nu Skin  Canada,  Inc.,  Nu Skin
International,  Inc. Blake Roney, et. al. which was filed with the United States
District Court for the District of Utah, Central Division (the "Court") in March
1993.  Ms.  Capone  filed a  class  action  complaint  against  NSI and  certain
affiliated parties (the  "Defendants").  The complaint alleges violations of the
anti-fraud  provisions of the Securities Act of 1933 and the Securities Exchange
Act of 1934,  common  law  fraud,  and  violations  of the Utah  Consumer  Sales
Practices  Act. The plaintiff also sought  injunctive  relief,  disgorgement  by
Defendants, and restitution to plaintiff of all earnings, profits, compensation,
and benefits  obtained by the  Defendants.  In June 1997, the Court denied NSI's
motion for summary judgment but also denied the plaintiff's  motion to certify a
similarly  situated  class  of  distributors.   In  May  1998  the  Court,  upon
reconsideration,  granted the plaintiff's motion to certify a similarly situated
class of  distributors  based on more limited claims under the Securities Act of
1933 and the Utah  Anti-Pyramid  statute.  The case continues in discovery.  The
Company's  potential  liability  associated with this case is limited by certain
indemnities  provided to the Company in connection  with the  acquisition by the
Company of NSI.

         At the time of the  Company's  acquisition  of  Pharmanex,  Inc. in the
fourth quarter of 1998,  Pharmanex was a party to an action entitled  Pharmanex,
Inc.  v. Donna  Shalala  which was filed by  Pharmanex  with the  United  States
District  Court for the District of Utah,  Central  Division  ("Court") in April
1997  after  the  Food  and  Drug

                                      -35-

Administration  informed  Pharmanex  that  it  considered  Pharmanex's  product,
CHOLESTIN,  to be a drug. The matter was held in abeyance pending an issuance of
a final  decision by the FDA. On May 20,  1998,  the FDA issued a "Final  Order"
announcing the FDA's  decision that it considers  CHOLESTIN to be a "drug" and a
"new drug" rather than a dietary supplement. On June 1, 1998, Pharmanex filed an
amended  complaint  requesting  the  Court  to find  that the FDA  decision  was
contrary to the law. On February 16, 1999,  the Court ruled that  CHOLESTIN  was
not a drug and could be legally  sold as a dietary  supplement.  There can be no
assurance  that the FDA will not  appeal  such  order,  or in the  event of such
appeal,  that the Company  would  prevail.  An adverse  decision on appeal could
restrict the ability of the Company to distribute CHOLESTIN in the United States

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         There  were no  matters  submitted  to a vote of the  security  holders
during the fourth quarter of the fiscal year ended December 31, 1998.

                                      -36-

                                    PART II

ITEM 5.  MARKET FOR REGISTRANTS COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

         The information  required by Item 5 of Form 10-K is incorporated herein
by reference from the  information  contained in the section  captioned  "Common
Stock" in the Company's  1998 Annual Report to  Stockholders,  sections of which
are  attached  hereto as Exhibit 13. On October 16, 1998,  the Company  issued a
total  of  3,777,992  shares  of Class A Common  Stock  to the  shareholders  of
Generation  Health Holdings,  Inc.  pursuant to the merger of Generation  Health
Holdings,  Inc.  with and into  Sage  Acquisition  Corporation,  a  wholly-owned
subsidiary  of the  Company.  The  issuance of such shares was made in a private
transaction  in  reliance  on the  exemptions  provided  by Section  4(2) of the
Securities Act of 1933, as amended, and Rule 506 of Regulation D.

ITEM 6.  SELECTED FINANCIAL DATA

         The information  required by Item 6 of Form 10-K is incorporated herein
by reference from the information  contained in the section captioned  "Selected
Financial Data" in the Company's 1998 Annual Report to Stockholders, sections of
which are attached hereto as Exhibit 13.

ITEM 7.  MANAGEMENTS  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
         OF OPERATIONS

         The information  required by Item 7 of Form 10-K is incorporated herein
by  reference  from  the   information   contained  in  the  section   captioned
"Management's  Discussion  and  Analysis of Financial  Condition  and Results of
Operations"  in the Company's  1998 Annual Report to  Stockholders,  sections of
which are attached hereto as Exhibit 13.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

         The information required by Item 7A of Form 10-K is incorporated herein
by  reference  from  the   information   contained  in  the  section   captioned
"Management's  Discussion  and  Analysis of Financial  Condition  and Results of
Operations  " and  Note  14 to  the  Consolidated  Financial  Statements  in the
Company's  1998 Annual  Report to  Stockholders,  sections of which are attached
hereto as Exhibit 13.

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

         The information  required by Item 8 of Form 10-K is incorporated herein
by reference to the Consolidated  Financial Statements and the related notes set
forth in the Company's 1998 Annual Report to Stockholders, sections of which are
attached hereto as Exhibit 13.

ITEM 9.  CHANGES  IN  AND  DISAGREEMENTS  WITH  ACCOUNTANTS  ON  ACCOUNTING  AND
         FINANCIAL DISCLOSURE

         None.

                                      -37-

                                    PART III

The  information  required  by Items 10,  11,  12, and 13 of Part III are hereby
incorporated by reference to the Company's  Definitive  Proxy Statement filed or
to be filed with the Securities and Exchange Commission not later than April 30,
1999.

                                     PART IV

ITEM 14.   EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

             (a) Documents filed as part of this Form 10-K:

                 1. Financial Statements (pursuant to Part II, Item 8)

                      Report of Independent Accountants

                      Consolidated Balance Sheets at December 31, 1997 and 1998

                      Consolidated Statements of Income for the years ended
                      December 31, 1996, 1997, and 1998

                      Consolidated  Statements of  Stockholders'  Equity for the
                      years ended December 31, 1996, 1997, and 1998

                      Consolidated Statements of Cash Flows for the years ended
                      December 31, 1996, 1997, and 1998

                      Notes to Consolidated Financial Statements

                 2.   Financial   Statement   Schedules:   Financial   statement
                      schedules have been omitted  because they are not required
                      or are not applicable, or because the required information
                      is shown in the financial statements or notes thereto.

                 3.   Exhibits:  The following Exhibits are filed with this Form
                      10-K:

                      Exhibit
                      Number     Exhibit Description
                      -------    -------------------

                      2.1        Stock  Acquisition  Agreement  between  Nu Skin
                                 Asia  Pacific,  Inc. and each of the persons on
                                 the signature pages thereof, dated February 27,
                                 1998,  incorporated by reference to Exhibit 2.1
                                 of the Company's Annual Report on Form 10-K for
                                 the year ended December 31, 1997.

                      2.2        Restated  Agreement and Plan of  Reorganization
                                 and Merger by and between Nu Skin  Enterprises,
                                 Inc.,   Sage   Acquisition    Corporation   and
                                 Generation  Health  Holdings,  Inc. dated as of
                                 October 16, 1998,  incorporated by reference to
                                 Exhibit 2.1 to the Company's  Current Report on
                                 Form 8-K filed November 2, 1998.

                                      -38-

                      3.1        Amended    and    Restated    Certificate    of
                                 Incorporation  of the Company  incorporated  by
                                 reference  to  Exhibit  3.1  to  the  Company's
                                 Registration  Statement  on Form S-1  (File No.
                                 333-12073) (the "Form S-1").

                      3.2        Certificate  of  Amendment  to the  Amended and
                                 Restated     Certificate    of    Incorporation
                                 incorporated by reference to Exhibit 3.1 of the
                                 Company's Quarterly Report on Form 10-Q for the
                                 quarterly period ended June 30, 1998.

                      3.3        Certificate  of  Designation,  Preferences  and
                                 Relative  Participating,  Optional,  and  Other
                                 Special   Rights   of   Preferred   Stock   and
                                 Qualification,   Limitations  and  Restrictions
                                 Thereof.

                      3.4        Amended  and  Restated  Bylaws  of the  Company
                                 incorporated by reference to Exhibit 3.2 to the
                                 Company's Form S-1.

                      4.1        Specimen Form of Stock  Certificate for Class a
                                 Common  Stock   incorporated  by  reference  to
                                 Exhibit 4.1 to the Company's Form S-1.

                      4.2        Specimen Form of Stock  Certificate for Class B
                                 Common  Stock   incorporated  by  reference  to
                                 Exhibit 4.2 to the Company's Form S-1.

                      10.1       Form of Indemnification Agreement to be entered
                                 into by and among the  Company  and  certain of
                                 its  officers  and  directors  incorporated  by
                                 reference to Exhibit 10.1 to the Company's Form
                                 S-1.

                      10.2       Intentionally left blank.

                      10.3       Employment  Contract,  dated December 12, 1991,
                                 by and  between  Nu Skin  Taiwan  and John Chou
                                 incorporated  by  reference  to Exhibit 10.3 to
                                 the Company's Form S-1.

                      10.4       Employment Agreement, dated May 1, 1993, by and
                                 between  Nu  Skin  Japan  and   Takashi   Bamba
                                 incorporated  by  reference  to Exhibit 10.4 to
                                 the Company's Form S-1.

                      10.5       Service  Agreement,  dated  January 1, 1996, by
                                 and  between  Nu Skin  Korea and  Sung-Tae  Han
                                 incorporated  by  reference  to Exhibit 10.5 to
                                 the Company's Form S-1.

                      10.6       Form of Purchase and Sale Agreement  between Nu
                                 Skin   Hong  Kong  and  NSI   incorporated   by
                                 reference to Exhibit 10.6 to the Company's Form
                                 S- 1.

                      10.7       Form of Licensing and Sales  Agreement  between
                                 NSI and each subsidiary (prior to the Company's
                                 acquisition  of NSI  and  other  than  Nu  Skin
                                 Korea)  incorporated  by  reference  to Exhibit
                                 10.7 to the Company's Form S-1.

                      10.8       Form of Regional Distribution Agreement between
                                 NSI  and Nu  Skin  Hong  Kong  incorporated  by
                                 reference to Exhibit 10.8 to the Company's Form
                                 S-1.

                                      -39-

                      10.9       Form  of   Wholesale   Distribution   Agreement
                                 between NSI and each  Subsidiary  (prior to the
                                 Company's  acquisition of NSI and other than Nu
                                 Skin Hong Kong)  incorporated  by  reference to
                                 Exhibit 10.9 to the Company's Form S-1.

                      10.10      Form of  Trademark/Tradename  License Agreement
                                 between NSI and each  subsidiary  (prior to the
                                 Company's  acquisition of NSI)  incorporated by
                                 reference  to  Exhibit  10.10 to the  Company's
                                 Form S-1.

                      10.11      Form of Management  Services  Agreement between
                                 Nu Skin  International  Management  Group, Inc.
                                 ("NSIMG")and  each  subsidiary  (prior  to  the
                                 Company's  acquisition of NSI)  incorporated by
                                 reference  to  Exhibit  10.11 to the  Company's
                                 Form S-1.

                      10.12      Form of Licensing and Sales  Agreement  between
                                 NSI and Nu Skin Korea incorporated by reference
                                 to Exhibit 10.12 to the Company's Form S-1.

                      10.13      Form of  Independent  Distributor  Agreement by
                                 and between NSI and Independent Distributors in
                                 Hong  Kong/Macau  incorporated  by reference to
                                 Exhibit 10.13 to the Company's Form S-1.

                      10.14      Form of  Independent  Distributor  Agreement by
                                 and between NSI and Independent Distributors in
                                 Japan  incorporated  by  reference  to  Exhibit
                                 10.14 to the Company's Form S-1.

                      10.15      Form of  Independent  Distributor  Agreement by
                                 and between NSI and Independent Distributors in
                                 South  Korea   incorporated   by  reference  to
                                 Exhibit 10.15 to the Company's Form S-1.

                      10.16      Form of  Independent  Distributor  Agreement by
                                 and between NSI and Independent Distributors in
                                 Taiwan  incorporated  by  reference  to Exhibit
                                 10.16 to the Company's Form S-1.

                      10.17      Nu Skin Asia Pacific, Inc. 1996 Stock Incentive
                                 Plan incorporated by reference to Exhibit 10.17
                                 to the Company's Form S-1.

                      10.18      Form of Bonus  Incentive  Plan  for  Subsidiary
                                 Presidents incorporated by reference to Exhibit
                                 10.18 to the Company's Form S-1.

                      10.19      Option Agreement by and between the Company and
                                 M. Truman Hunt  incorporated  by  reference  to
                                 Exhibit 10.19 to the Company's Form S-1.

                      10.20      Form of Mutual Indemnification Agreement by and
                                 between  the Company  and NSI  incorporated  by
                                 reference  to  Exhibit  10.20 to the  Company's
                                 Form S-1.

                      10.21      Manufacturing Sublicense Agreement,  dated July
                                 27, 1995,  by and between NSI and Nu Skin Japan
                                 incorporated  by reference to Exhibit  10.21 to
                                 the Company's Form S-1.

                      10.22      1996  Option   Agreement  by  and  between  the
                                 Company and NSI  incorporated  by  reference to
                                 Exhibit 10.22 to the Company's Form S-1.

                                      -40-

                      10.23      Form  of  Addendum  to  Amended  and   Restated
                                 Licensing and Sales  Agreement  incorporated by
                                 reference  to  Exhibit  10.23 to the  Company's
                                 Form S-1.

                      10.24      Form  of  Administrative   Services   Agreement
                                 incorporated  by reference to Exhibit  10.24 to
                                 the Company's Form S-1.

                      10.25      Form  of  Amended  and  Restated   Stockholders
                                 Agreement   dated  as  of  November  28,  1997,
                                 incorporated  by reference to Exhibit  10.25 to
                                 the  Company's  Annual  Report on Form 10-K for
                                 the year ended December 31, 1997.

                      10.26      Demand   Promissory   Note   in  the   original
                                 principal  amount of $5,000,000  dated December
                                 10,  1997,  from Nedra D.  Roney  payable to Nu
                                 Skin  Asia  Pacific,   Inc.   incorporated   by
                                 reference  to  Exhibit  10.26 to the  Company's
                                 Annual  Report on Form 10-K for the year  ended
                                 December 31, 1997.

                      10.27      Stock  Pledge  Agreement  between  Nu Skin Asia
                                 Pacific,  Inc.  and  Nedra  Roney  dated  as of
                                 December 10, 1997, incorporated by reference to
                                 Exhibit 10.27 to the Company's Annual Report on
                                 Form  10-K  for the  year  ended  December  31,
                                 1997.

                      10.28      Stock Purchase  Agreement  dated as of December
                                 10, 1997,  between Nu Skin Asia  Pacific,  Inc.
                                 and  Kirk  V.  Roney  and   Melanie  R.  Roney,
                                 incorporated  by reference to Exhibit  10.28 to
                                 the  Company's  Annual  Report on Form 10-K for
                                 the year ended December 31, 1997.

                      10.29      Stock Purchase  Agreement  dated as of December
                                 10, 1997,  between Nu Skin Asia  Pacific,  Inc.
                                 and  Rick  A.  Roney  and  certain  affiliates,
                                 incorporated  by reference to Exhibit  10.29 to
                                 the  Company's  Annual  Report on Form 10-K for
                                 the year ended December 31, 1997.

                      10.30      Stock Purchase  Agreement  dated as of December
                                 10, 1997,  between Nu Skin Asia  Pacific,  Inc.
                                 and Burke F. Roney,  incorporated  by reference
                                 to Exhibit 10.30 to the Company's Annual Report
                                 on Form 10-K for the year  ended  December  31,
                                 1997.

                      10.31      Stock  Purchase  Agreement  dated  December 10,
                                 1997,  between Nu Skin Asia  Pacific,  Inc. and
                                 Park R. Roney,  incorporated  by  reference  to
                                 Exhibit 10.31 to the Company's Annual Report on
                                 Form 10-K for the year ended December 31, 1997.

                      10.32      Stock  Purchase  Agreement  dated  December 10,
                                 1997,  between Nu Skin Asia  Pacific,  Inc. and
                                 The MAR  Trust  incorporated  by  reference  to
                                 Exhibit 10.32 to the Company's Annual Report on
                                 Form 10-K for the year ended December 31, 1997.

                      10.33      Form of  Management  Services  Agreement by and
                                 each of  between  NSIMG and Nu Skin  USA,  Inc.
                                 ("Nu Skin  USA") and the other  North  American
                                 Affiliates.

                      10.34      Form of Wholesale Distribution Agreement by and
                                 between  NSI and  each  of Nu Skin  USA and the
                                 other North American Affiliates.

                                      -41-

                      10.35      Form of  Licensing  and Sales  Agreement by and
                                 between  NSI and each Nu Skin USA and the other
                                 North American Affiliates.

                      10.36      Form of Trademark\Tradename Licensing Agreement
                                 by and  between NSI and each of Nu Skin USA and
                                 the other North American Affiliates.

                      10.37      Tax Sharing and Indemnification Agreement dated
                                 December  31,  1997,  by and among NSI, Nu Skin
                                 USA,  and the  shareholders  of NSI and Nu Skin
                                 USA and their successors and assigns.

                      10.38      Assumption of Liabilities  and  Indemnification
                                 Agreement  dated  December  31,  1997,  by  and
                                 between NSI and Nu Skin USA.

                      10.39      Employee Benefits  Allocation  Agreement by and
                                 between NSI and Nu Skin USA.

                      10.40      Form of Licensing Agreement between NSI and Big
                                 Planet.

                      10.41      Form of Management  Services  Agreement between
                                 NSI and Big Planet.

                      10.42      Warehouse  Lease  Agreement  dated  March 1996,
                                 between NSI and Aspen Investments, Ltd.

                      10.43      Lease  Agreement dated January 27, 1995, by and
                                 between NSI and Scrub Oak, Ltd.

                      10.44      Sublease  Agreement  dated  January 1, 1998, by
                                 and between NSI and Nu Skin USA.

                      10.45      Warehouse Lease Agreement (Annex) dated October
                                 1,  1993,   by  and   between   NSI  and  Aspen
                                 Investments, Ltd.

                      10.46      Contribution and  Distribution  Agreement dated
                                 as of December 31, 1997,  by and between NSI an
                                 Nu Skin USA.

                      10.47      Form of the Company's  Employee Incentive Bonus
                                 Plan.

                      10.48      Amendment in Total and Complete  Restatement of
                                 Deferred Compensation Plan.

                      10.49      Form of Deferred Compensation Plan (New Form).

                      10.50      Amendment in Total and Complete  Restatement of
                                 NSI Compensation Trust.

                      10.51      Employment  Agreement by and between Pharmanex,
                                 Inc. and William McGlashan, Jr.

                                      -42-

                      10.52      Asset  Purchase  Agreement  by  and  among  the
                                 Company,  Nu Skin United  States,  Inc., and Nu
                                 Skin USA, dated as of March 8, 1999.

                      10.53      Termination Agreement by and between NSI and Nu
                                 Skin USA, dated as of March 8, 1999.

                      10.54      Indemnification  Limitation  Agreement  by  and
                                 among the Company, Nu Skin United States, Inc.,
                                 NSI,  Nu Skin USA,  and the other  parties  who
                                 executed such agreement.

                      10.55      Amendment   No.  1  to  Amended  and   Restated
                                 Stockholders Agreement dated as of November 28,
                                 1997.

                      13         1998 Annual Report to Stockholders  (Only items
                                 incorporated by reference).

                      21.1       Subsidiaries of the Company.

                      23.1       Consent of PricewaterhouseCoopers LLP.

                      23.2       Consent and Report of Grant Thornton LLP.

                      27.        Financial Data Schedule.

             (B) The Company  filed two  Current  Reports on Form 8-K during the
                 last quarter of the period covered by this report.

                 On October 6, 1998,  the Company filed a Current Report on Form
                 8-K to report that it had entered into an agreement to purchase
                 Generation  Health  Holdings,   Inc.,  the  parent  company  of
                 Pharmanex.

                 On November 2, 1998, the Company filed a Current Report on Form
                 8-K  to  report  that  it  had  completed  the  acquisition  of
                 Generation Health Holdings, Inc. on October 16, 1998.

             (c) The  exhibits  required  by  Item 601 of Regulation S-K are set
                 forth in (a)3 above.

             (d) The financial statement schedules  required  by Regulation  S-K
                 are set forth in (a)2 above.

                                      -42-

                                   SIGNATURES

         Pursuant to the  requirements  of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on March 30, 1999.
                                            NU SKIN ENTERPRISES, INC.

                                            By:   /s / Steven J. Lund
                                                  Steven J. Lund, President
                                                  and Chief Executive Officer

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
this  report has been  signed  below by the  following  persons on behalf of the
Registrant and in the capacities indicated on March 30, 1999.

         Signature                          Capacity in Which Signed
----------------------------    ------------------------------------------------

/s/  Blake M. Roney             Chairman of the Board
Blake M. Roney

/s/  Steven J. Lund             President, Chief Executive Officer, and Director
Steven J. Lund                  (Principal Executive Officer)

/s/ Corey B. Lindley            Chief Financial Officer (Principal Financial
Corey B. Lindley                Officer and Accounting Officer)

/s/ Sandra N. Tillotson         Senior Vice President, Director
Sandra N. Tillotson

/s/ Keith R. Halls              Senior Vice President, Director
Keith R. Halls

/s/ Brooke B. Roney             Senior Vice President, Director
Brooke B. Roney

/s/ Daniel W. Campbell          Director
Daniel W. Campbell

/s/ E. J. "Jake" Garn           Director
E. J. "Jake" Garn

/s/ Paula Hawkins               Director
Paula Hawkins

/s/ Max L. Pinegar              Director
Max L. Pinegar

                                  EXHIBIT INDEX

Exhibit
Number       Exhibit Description
-------      -------------------
2.1          Stock Acquisition  Agreement between Nu Skin Asia Pacific, Inc. and
             each of the persons on the signature pages thereof,  dated February
             27, 1998, incorporated by reference to Exhibit 2.1 of the Company's
             Annual Report on Form 10-K for the year ended December 31, 1997.

2.2          Restated  Agreement  and Plan of  Reorganization  and Merger by and
             between Nu Skin Enterprises, Inc., Sage Acquisition Corporation and
             Generation  Health  Holdings,  Inc.  dated as of October 16,  1998,
             incorporated  by reference to Exhibit 2.1 to the Company's  Current
             Report on Form 8-K filed November 2, 1998.

3.1          Amended and Restated  Certificate of  Incorporation  of the Company
             incorporated   by  reference  to  Exhibit  3.1  to  the   Company's
             Registration  Statement on Form S-1 (File No. 333-12073) (the "Form
             S-1").

3.2          Certificate of Amendment to the Amended and Restated Certificate of
             Incorporation  incorporated  by  reference  to  Exhibit  3.1 of the
             Company's  Quarterly  Report on Form 10-Q for the quarterly  period
             ended June 30, 1998.

3.3          Certificate of Designation, Preferences and Relative Participating,
             Optional,   and  Other  Special  Rights  of  Preferred   Stock  and
             Qualification, Limitations and Restrictions Thereof.

3.4          Amended  and  Restated  Bylaws  of  the  Company   incorporated  by
             reference to Exhibit 3.2 to the Company's Form S-1.

4.1          Specimen  Form  of  Stock  Certificate  for  Class a  Common  Stock
             incorporated by reference to Exhibit 4.1 to the Company's Form S-1.

4.2          Specimen  Form  of  Stock  Certificate  for  Class B  Common  Stock
             incorporated by reference to Exhibit 4.2 to the Company's Form S-1.

10.1         Form of  Indemnification  Agreement to be entered into by and among
             the Company and certain of its officers and directors  incorporated
             by reference to Exhibit 10.1 to the Company's Form S-1.

10.2         Intentionally left blank.

10.3         Employment  Contract,  dated  December 12, 1991,  by and between Nu
             Skin Taiwan and John Chou incorporated by reference to Exhibit 10.3
             to the Company's Form S-1.

10.4         Employment  Agreement,  dated May 1, 1993,  by and  between Nu Skin
             Japan and Takashi Bamba  incorporated  by reference to Exhibit 10.4
             to the Company's Form S-1.

10.5         Service  Agreement,  dated  January 1, 1996, by and between Nu Skin
             Korea and Sung-Tae Han incorporated by reference to Exhibit 10.5 to
             the Company's Form S-1.

10.6         Form of Purchase and Sale  Agreement  between Nu Skin Hong Kong and
             NSI incorporated by reference to Exhibit 10.6 to the Company's Form
             S-1.

10.7         Form  of  Licensing  and  Sales  Agreement  between  NSI  and  each
             subsidiary  (prior to the  Company's  acquisition  of NSI and other
             than Nu Skin Korea)  incorporated  by  reference to Exhibit 10.7 to
             the Company's Form S-1.

Exhibit
Number       Exhibit Description
-------      -------------------
10.8         Form of  Regional  Distribution  Agreement  between NSI and Nu Skin
             Hong  Kong  incorporated  by  reference  to  Exhibit  10.8  to  the
             Company's Form S-1.

10.9         Form of  Wholesale  Distribution  Agreement  between  NSI and  each
             Subsidiary  (prior to the  Company's  acquisition  of NSI and other
             than Nu Skin Hong Kong)  incorporated  by reference to Exhibit 10.9
             to the Company's Form S-1.

10.10        Form of Trademark/Tradename  License Agreement between NSI and each
             subsidiary (prior to the Company's acquisition of NSI) incorporated
             by reference to Exhibit 10.10 to the Company's Form S-1.

10.11        Form of Management Services Agreement between Nu Skin International
             Management Group,  Inc.  ("NSIMG")and each subsidiary (prior to the
             Company's  acquisition of NSI) incorporated by reference to Exhibit
             10.11 to the Company's Form S-1.

10.12        Form of Licensing and Sales Agreement between NSI and Nu Skin Korea
             incorporated  by reference to Exhibit 10.12 to the  Company's  Form
             S-1.

10.13        Form of  Independent  Distributor  Agreement by and between NSI and
             Independent   Distributors  in  Hong  Kong/Macau   incorporated  by
             reference to Exhibit 10.13 to the Company's Form S-1.

10.14        Form of  Independent  Distributor  Agreement by and between NSI and
             Independent  Distributors  in Japan  incorporated  by  reference to
             Exhibit 10.14 to the Company's Form S-1.

10.15        Form of  Independent  Distributor  Agreement by and between NSI and
             Independent  Distributors in South Korea  incorporated by reference
             to Exhibit 10.15 to the Company's Form S-1.

10.16        Form of  Independent  Distributor  Agreement by and between NSI and
             Independent  Distributors  in Taiwan  incorporated  by reference to
             Exhibit 10.16 to the Company's Form S-1.

10.17        Nu Skin Asia Pacific,  Inc. 1996 Stock Incentive Plan  incorporated
             by reference to Exhibit 10.17 to the Company's Form S-1.

10.18        Form of Bonus Incentive Plan for Subsidiary Presidents incorporated
             by reference to Exhibit 10.18 to the Company's Form S-1.

10.19        Option  Agreement  by and  between  the  Company and M. Truman Hunt
             incorporated  by reference to Exhibit 10.19 to the  Company's  Form
             S-1.

10.20        Form of Mutual Indemnification Agreement by and between the Company
             and NSI incorporated by reference to Exhibit 10.20 to the Company's
             Form S-1.

10.21        Manufacturing  Sublicense  Agreement,  dated July 27, 1995,  by and
             between NSI and Nu Skin Japan  incorporated by reference to Exhibit
             10.21 to the Company's Form S-1.

10.22        1996  Option   Agreement   by  and  between  the  Company  and  NSI
             incorporated  by reference to Exhibit 10.22 to the  Company's  Form
             S-1.

10.23        Form of  Addendum  to  Amended  and  Restated  Licensing  and Sales
             Agreement  incorporated  by  reference  to  Exhibit  10.23  to  the
             Company's Form S-1.

Exhibit
Number       Exhibit Description
-------      -------------------
10.24        Form of Administrative Services Agreement incorporated by reference
             to Exhibit 10.24 to the Company's Form S-1.

10.25        Form of Amended and  Restated  Stockholders  Agreement  dated as of
             November 28, 1997,  incorporated  by reference to Exhibit  10.25 to
             the  Company's  Annual  Report  on Form  10-K  for the  year  ended
             December 31, 1997.

10.26        Demand  Promissory  Note  in  the  original   principal  amount  of
             $5,000,000  dated December 10, 1997, from Nedra D. Roney payable to
             Nu Skin Asia  Pacific,  Inc.  incorporated  by reference to Exhibit
             10.26 to the  Company's  Annual  Report  on Form  10-K for the year
             ended December 31, 1997.

10.27        Stock Pledge Agreement between Nu Skin Asia Pacific, Inc. and Nedra
             Roney dated as of December 10, 1997,  incorporated  by reference to
             Exhibit 10.27 to the  Company's  Annual Report on Form 10-K for the
             year ended December 31, 1997..

10.28        Stock Purchase  Agreement dated as of December 10, 1997, between Nu
             Skin Asia  Pacific,  Inc.  and Kirk V. Roney and  Melanie R. Roney,
             incorporated by reference to Exhibit 10.28 to the Company's  Annual
             Report on Form 10-K for the year ended December 31, 1997.

10.29        Stock Purchase  Agreement dated as of December 10, 1997, between Nu
             Skin Asia Pacific,  Inc. and Rick A. Roney and certain  affiliates,
             incorporated by reference to Exhibit 10.29 to the Company's  Annual
             Report on Form 10-K for the year ended December 31, 1997.

10.30        Stock Purchase  Agreement dated as of December 10, 1997, between Nu
             Skin  Asia  Pacific,  Inc.  and  Burke F.  Roney,  incorporated  by
             reference to Exhibit 10.30 to the  Company's  Annual Report on Form
             10-K for the year ended December 31, 1997.

10.31        Stock Purchase  Agreement dated December 10, 1997,  between Nu Skin
             Asia Pacific, Inc. and Park R. Roney,  incorporated by reference to
             Exhibit 10.31 to the  Company's  Annual Report on Form 10-K for the
             year ended December 31, 1997.

10.32        Stock Purchase  Agreement dated December 10, 1997,  between Nu Skin
             Asia Pacific,  Inc. and The MAR Trust  incorporated by reference to
             Exhibit 10.32 to the  Company's  Annual Report on Form 10-K for the
             year ended December 31, 1997.

10.33        Form of Management  Services Agreement by and each of between NSIMG
             and Nu Skin USA, Inc. ("Nu Skin USA") and the other North  American
             Affiliates.

10.34        Form of  Wholesale  Distribution  Agreement  by and between NSI and
             each of Nu Skin USA and the other North American Affiliates.

10.35        Form of Licensing  and Sales  Agreement by and between NSI and each
             Nu Skin USA and the other North American Affiliates.

10.36        Form of Trademark\Tradename  Licensing Agreement by and between NSI
             and   each  of  Nu  Skin   USA  and  the   other   North   American
             Affiliates.10.33  Management  Services Agreement dated December 31,
             1997, by and between NSIMG and Nu Skin USA, Inc. ("Nu Skin USA").

Exhibit
Number       Exhibit Description
-------      -------------------
10.37        Tax Sharing and Indemnification  Agreement dated December 31, 1997,
             by and among NSI, Nu Skin USA, and the  shareholders  of NSI and Nu
             Skin USA and their successors and assigns.

10.38        Assumption  of  Liabilities  and  Indemnification  Agreement  dated
             December 31, 1997, by and between NSI and Nu Skin USA.

10.39        Employee  Benefits  Allocation  Agreement by and between NSI and Nu
             Skin USA.

10.40        Form of Licensing Agreement between NSI and Big Planet.

10.41        Form of Management Services Agreement between NSI and Big Planet.

10.42        Warehouse Lease  Agreement dated March 1996,  between NSI and Aspen
             Investments, Ltd.

10.43        Lease  Agreement  dated  January 27,  1995,  by and between NSI and
             Scrub Oak, Ltd.

10.44        Sublease Agreement dated January 1, 1998, by and between NSI and Nu
             Skin USA.

10.45        Warehouse  Lease  Agreement  (Annex)  dated October 1, 1993, by and
             between NSI and Aspen Investments, Ltd.

10.46        Contribution  and  Distribution  Agreement dated as of December 31,
             1997, by and between NSI an Nu Skin USA.

10.47        Form of the Company's Employee Incentive Bonus Plan.

10.48        Amendment   in  Total  and   Complete   Restatement   of   Deferred
             Compensation Plan.

10.49        Form of Deferred Compensation Plan (New Form).

10.50        Amendment in Total and  Complete  Restatement  of NSI  Compensation
             Trust.

10.51        Employment  Agreement  by and between  Pharmanex,  Inc. and William
             McGlashan, Jr.

10.52        Asset Purchase  Agreement by and among the Company,  Nu Skin United
             States, Inc., and Nu Skin USA, dated as of March 8, 1999.

10.53        Termination  Agreement by and between NSI and Nu Skin USA, dated as
             of March 8, 1999.

10.54        Indemnification  Limitation  Agreement by and among the Company, Nu
             Skin United States,  Inc.,  NSI, Nu Skin USA, and the other parties
             who executed such agreement.

10.55        Amendment  No. 1 to Amended  and  Restated  Stockholders  Agreement
             dated as of November 28, 1997.

13           1998 Annual  Report to  Stockholders  (Only items  incorporated  by
             reference).

Exhibit
Number       Exhibit Description
-------      -------------------

21.1         Subsidiaries of the Company.

23.1         Consent of PricewaterhouseCoopers LLP.

23.2         Consent and Report of Grant Thornton LLP.

27.          Financial Data Schedule.